Tyrosine kinase biosensors and methods of use

ABSTRACT

Disclosed are compositions and methods for measuring tyrosine kinase activity.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. patent applicationserial number 13/761,968, filed Feb. 7, 2013 which claims the benefit ofpriority to U.S. provisional application numbers 61/595,959 filed Feb.7, 2012, 61/603,752 filed Feb. 27, 2012, 61/605,591 filed Mar. 1, 2012,61/693,002 filed. Aug. 24, 2012, 61/704,298 filed. Sep. 21, 2012, and61/736,312 filed Dec. 12, 2012, each of which is incorporated byreference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with governments support under Grant Nos.R25CA128770, R00CA127161, CA037372, and R21CA160129 awarded by theNational Institutes of Health, National Cancer Institute. The UnitedStates Government has certain rights in the invention.

SEQUENCE LISTING

Incorporated by reference in its entirety herein is a computer-readablesequence listing electronically filed with this application.

INTRODUCTION

Spleen tyrosine kinase (Syk) is a 72 kDa non-receptor tyrosine kinasefirst isolated from bovine thymus and porcine spleen best known for itsrole in B lymphocyte development and activation. Loss of Syk expressionresults in perinatal lethality in mice and an arrest in the developmentof B cells. Upon antigen binding to B cell antigen receptor (BCR), Lyn,a Src family kinase, initiates phosphorylation of immunoreceptortyrosine-based activation motifs (ITAMs) on components of the BCR.Phosphorylation of the ITAMs results in recruitment and activation ofSyk, and phosphorylation of multiple Syk tyrosine residues. Followingactivation of Syk, numerous signaling pathways are initiated, leading toactivation of downstream transcription factors, ultimately resulting ininduction of cell proliferation and differentiation.

Dysregulation of the expression or the activity of Syk contributes tovarious disease states, making it a potential therapeutic target. Sykhas been implicated as a factor in rheumatological disorders (such asrheumatoid arthritis) and malignant diseases of myeloid, lymphocytic andepithelial origin. For example, Syk was found to be constitutivelyactive in primary blasts from a set of patients with acute myeloidleukemia (AML). Inhibition of Syk decreased the viability of these AMLblasts in vitro and reduced the number of these cells infiltratingspleen and bone marrow in a mouse xenograft model. In some chroniclymphocytic leukemia cells (B-CLL), Syk is hyperactive despiteexhibiting normal expression levels, and inhibition of Syk or silencingof Syk expression via siRNA decreases cell viability. Further, severalperipheral T-cell lymphomas (PTCLs) exhibit aberrant expression of Syk.In these cells, siRNA silencing of Syk translation or inhibition of itskinase activity with a specific kinase inhibitor (R406, RigelPharmaceuticals) induces apoptosis and blocks proliferation in cellswith elevated Syk Y525/Y526 phosphorylation. These results suggest thatSyk could be a novel therapeutic target for the treatment of PTCLs.Conversely, in breast cancer, which has an epithelial origin. Sykappears to have tumor suppressor functions, in that Syk is expressed innormal breast epithelia, whereas there is little to no Syk present inmetastatic breast cancer cells. Expression of Syk negatively affectsmotility and invasion in these carcinomas.

The ability to measure Syk activity would guide treatment of certaincancers and facilitate development of novel therapeutics. Methods ofmeasuring Syk activity currently in use include in vitro kinase assays,luciferase reporter assays of downstream transcription factors, andphosphotyrosine antibody-based detection. Each of these methods hasdrawbacks that make them less than optimal for the clinical setting. Invitro kinase assays measure Syk activity post lysis. Therefore, if usinga whole cell lysate, proteins such as c-Cbl that normally modulate thefunction of the kinase (and which are known to be critical for obtainingbiologically-relevant activation especially for Syk) can becomeseparated from Syk; also, proteins normally found in differentsubcellular compartments could artifactually interact with Syk and alterits activity. Also, as a result of phosphatase activity and Sykautophosphorylation, the state of phosphorylation and activity of Sykcan change during in vitro kinase assays in ways that may not berelevant to its intracellular activity in a disease context. Whiletranscription factor-driven luciferase reporter assays are performed inwhole cells, they are an indirect measure of Syk activity as there arenumerous proteins in the pathways between Syk and the transcriptionfactors and thus may be confounded by disruption of additionalcomponents of these cascades. Phosphotyrosine antibody-based methodssuch as Western blots and Phosphoflow cytometry use phosphorylationsites in endogenous proteins, such as known Syk-targeted sites and/orSyk autophosphorylation sites, as surrogate reporters of Syk activity.However, phosphorylation at endogenous sites may be occurring fromkinases other than Syk, such as Lyn, so specificity can be difficult toconfirm. Additionally, Syk is phosphorylated on multiple sites includingsome that negatively regulate the kinase. Besides this, antibodies forevery potentially meaningful site of Syk phosphorylation are notavailable, and their development is subject to the uncertaintiesinherent in epitope and antibody generation. Therefore, an ideal methodto measure Syk activity would be one that specifically monitors theability of the kinase to catalyze a phosphotransferase reaction in anintact cell.

There is a need in the art for compositions and methods of measuringactivity of tyrosine kinases, including Syk kinase. The compositions andmethods described herein address that need.

SUMMARY

The present invention relates generally to compositions and methods forassaying tyrosine kinase activity, and to methods for identifyingsuitable peptide sequences for use in the assays.

In certain embodiments, the invention includes a biosensor comprising apeptide comprising a substrate sequence, i.e., an amino acid sequenceincluding a tyrosine residue that can be phosphorylated by a tyrosinekinase. In certain embodiments, the biosensor includes a substratesequence that can be phosphorylated by Syk, Btk, one or more Src familytyrosine kinases, Jak2, or Abl. In certain embodiments, the biosensorincludes one or more additional functional elements. In someembodiments, the functional elements include an affinity tag tofacilitate capture, isolation or immobilization of the biosensor, and/ora cleavable linker, and/or a cell penetrating peptide. In certainembodiments, the biosensor may include an affinity tag, such as biotinor a poly-His tag. In certain embodiments, the biosensor may include acell penetrating peptide. In certain embodiments, the cell penetratingpeptide may be Tat. In certain embodiments, the biosensor may includesuch as a cleavable linker, such as a photocleavable linker. Thephotocleavable linker may include, for example, a photocleavable aminoacid analog such as beta(nitrophenyl)alanine. The photocleavable linkercovalently links two other elements of the biosensor. For example, thesubstrate sequence may be linked to an affinity tagged peptide sequencewhich is in turn linked through a photocleavable linker to a cellpenetrating peptide. In other embodiments, the biosensor is designed toinclude photocleavable linker between the substrate sequence andaffinity tag.

In certain embodiments, the biosensor comprises a substrate sequence forSyk, Btk, one or more Src family tyrosine kinases, Jak2, or Abl.

In certain embodiments, the composition may include a Syk-specificbiosensor comprising a substrate sequence selected from the groupconsisting of DEEDYEEPD (SEQ ID NO:1), DEEDYEEPDEP (SEQ ID NO:2),EEDDYESPN(SEQ ID NO:3), EEDSYESPN(SEQ ID NO:4), EEDSYDSPN(SEQ ID NO:5),EEDDYESPNEP (SEQ ID NO:6), EEDSYESPNEP (SEQ ID NO:7), EEDSYDSPNEP (SEQID NO:8), GGEEDDYESPNEPGG (SEQ ID NO:9), GGEEDSYESPNEPGG (SEQ ID NO:10),GGEEDSYDSPNEPGG (SEQ ID NO:11), GGDEEDYEEPDEPGG (SEQ ID NO:12), and isGGEEDSYDSPNGG (SEQ ID NO:13).

In certain embodiments, the composition may include a Btk-specificbiosensor that includes ELDAYLENE (SEQ ID NO:14), ELAGYLENE (SEQ IDNO:15), ELDVYEEQL (SEQ ID NO:16), or ELDVYVEQT (SEQ ID NO:17).

In certain embodiments, the composition may include a Srcfamily-specific biosensor that has includes DEDIYEELD (SEQ ID NO:18),EGDVYDFVE (SEQ ID NO:19), NNDVYEQPE (SEQ ID NO:20), EEDVYDMPD (SEQ IDNO:21), EADVYDMPD (SEQ ID NO:22), DLDIYEELD (SEQ ID NO:23), or EAHVYDMMD(SEQ ID NO:24).

In certain embodiments, the composition may include a Jak2-specificbiosensor that has includes DPDRYIRTE (SEQ ID NO:25), EGDRYLKLE (SEQ IDNO:26), EDGRYVQLD (SEQ ID NO:27), or PKPRYVQLD (SEQ ID NO:28).

In certain embodiments, the composition may include an Abl-specificbiosensor that includes DEVAYQAPF (SEQ ID NO:29), DFIRYHFWV (SEQ IDNO:30), DHIFYIIPV (SEQ ID NO:31), or DHIFYHIPV (SEQ ID NO:32).

In other embodiments are provided methods for detecting tyrosine kinaseactivity. In certain embodiments, the methods allow detection of theactivity of Syk, Btk, one or more Src family tyrosine kinases, Jak2, orAbl by detecting phosphorylation of a substrate sequence of Syk, Btk, aSrc family kinase, Jak2, or Abl. In certain embodiments, the methodsallow “multiplexing” of the detection of tyrosine kinase activity, i.e.,detecting the activity of two or more tyrosine kinases in a singlereaction. In certain embodiments, the assay is conducted in vitro or inwhole cells. In certain embodiments, phosphorylation is detected usingELISA, terbium based time-resolved luminescence, MALDI-TOF MS analysis,or multiple reaction monitoring (MRM) on a triple quadrupole massspectrometer. In certain embodiments, the method is conducted using asubstrate sequence or a biosensor comprising the substrate thatcovalently attached directly or indirectly through an affinity tag to asolid surface, such as a bead, a multi-well plate, or nanoparticle.

In certain embodiments, the methods of the invention may be used todetermine the level of tyrosine kinase activity in a biological samplefrom a mammal, such as a human. In certain embodiments, the methodsinvolve detecting Syk activity in a sample from a person suspected ofhaving or risk for developing a condition associated with alteredtyrosine kinase activity increased, i.e., tyrosine kinase activity thatis increased or decreased relative to the tyrosine kinase activity of acontrol, e.g., a sample from a person who does not have the condition,or a normal range of tyrosine kinase activity based on the tyrosinekinase activities of samples from a relevant sample of people. Incertain embodiments, the sample includes lymphocytic cells, myeloidcells, or cancer cells of epithelial origin. In certain embodiments, theresults of the determination may be used in diagnosis or prognosis, orin determining a course of treatment.

In certain embodiments, the methods involve determining the level of Sykactivity in a person. In certain embodiments, the person has acutemyeloid leukemia (AML). In certain embodiments, the method may involverecommending treatment or treating a person with AML having an increasedlevel of Syk activity relative to a control with a Syk inhibitor. Incertain embodiments, the method involves determining the level of Sykactivity in a person with chronic lymphocytic leukemia cells (B-CLL). Incertain embodiments, the method may involve recommending treatment ortreating a person with B-CLL having an increased level of Syk activityrelative to a control with a Syk inhibitor Syk. In certain embodimentsin which the person has a disorder associated with increased Sykactivity, treatment may include administering to the person an effectiveamount of a Syk inhibitor, such as an siRNA or small molecule Sykinhibitor, some of which are known in the art. In certain embodiments,the method may involve recommending treatment or treating a person withperipheral T-cell lymphomas (PTCLs) In certain embodiments in which theperson has a disorder associated with increased Syk activity, treatmentmay include administering to the person an effective amount of a Sykinhibitor, such as an siRNA or small molecule Syk inhibitor, some ofwhich are known in the art.

In certain embodiments, the methods involve determining the level of Sykactivity in a sample from a person with breast cancer. In certainembodiments, the method involves recommending treatment or treating aperson with breast cancer cells having reduced expression of Syk, thetreatment including administering an effective amount of a Syk agonist,a Syk kinase, or a genetic construct expressing Syk kinase.

In certain embodiments, the methods can be used to determine whether aperson with a cancer is likely to benefit from a particular treatment.For example, in certain embodiments, the methods of the invention can beused to detect tyrosine kinase activity in whole cells obtained from theperson in the presence and absence of an inhibitor of the tyrosinekinase. In certain embodiments, the methods employ an Abl biosensor tomeasure phosphorylation of in whole cells from a person with chronicmyelogenous leukemia (CML) to assess whether the cells are sensitive orresistant to treatment with imatinib. In certain embodiments,phosphorylation levels of cells treated or not treated with imatinib invitro are compared, with the absence of a sufficient decrease inphosphorylation of the substrate sequence from imatinib treated cellssuggesting that the cancer may not respond to treatment with theinhibitor. In other embodiments, samples are taken from the person withCML at different times to monitor effectiveness as measured by asustained decrease in phosphorylation of the Abl biosensor followingtreatment with imatinib. In certain embodiments, the methods areperformed using MRM on a triple quadrupole mass spectrometer usingrelatively few cells, e.g., from 10,000 to 50,000 cells, making testingof clinical samples feasible.

In other embodiments, the methods of the invention can be used to screenfor molecules capable of altering tyrosine kinase activity, includingmolecules that reduce or increase tyrosine kinase activity. In certainembodiments are provided methods for screening for inhibitors of Syk,Btk, one or more Src family tyrosine kinases, Jak2, or Abl. In certainembodiments, the assays are conducted in a high throughput format. Incertain embodiments, the methods employ whole cells that are contactedwith the biosensor in the presence and absence of the test molecule toassess whether the agent inhibits intracellular phosphorylation of thesubstrate sequence.

In certain embodiments are provided kits comprising peptide substrates,for example, peptide substrate immobilized on a solid surface, orcomprised within a biosensor. In certain embodiments, the kits may beused to perform the methods of the invention. In certain embodiments,the kits may contain additional components, including, for example,suitable buffers, Syk, and a phosphorylation detection reagent such asantibodies or terbium.

In certain embodiments, the present invention includes a method fordesigning peptide substrates for a kinase. The method may be used toidentify substrates for tyrosine kinases and serine/threonine kinases.The method involves calculating a positional scoring matrix (PSM) usinga positional probability matrix of using sequence of known substratesand empirical data developed using a positional screening peptidelibrary. In some embodiments, the PSM is used to generate akinase-focused peptide library. The members of the library are assayedfor the ability to serve as a substrate for the tyrosine kinase ofinterest, and are screened using other kinases to identify substratesspecific for the kinase of interest.

In certain embodiments, sequences with high PSM are aligned with aterbium binding motif, and selected for inclusion in the kinase-focusedpeptide library based on similarity to the motif or are modified toenhance activity.

In certain embodiments, the kinase focused library is screened for theability to bind terbium in a phosphorylation dependent manner.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows the sequence alignment of a peptide from α-synuclein(α-syn Y125) an atypical sensitizing peptide, and SAStide.

FIG. 1B shows steady-state luminescence plots for SAStide and pSAStideand Tb.

FIG. 1C shows time-resolved luminescence emission pSAStide, SAStide, andTb.

FIG. 2 is a schematic representation illustrating the concept oftime-resolved luminescence in the detection of Syk activity usingSAStide.

FIG. 3A shows pSAStide-Tb³⁺ luminescence emission spectra in thepresence of the quenched Syk in vitro kinase assay buffer. FIG. 3B showsemission spectral area calibration curve based on percentphosphorylation in vitro. FIG. 3C shows in vitro Syk kinase assayluminescence emission spectra. FIG. 3D shows interpolated percentphosphorylation from Syk in vitro kinase assay.

FIG. 4A shows in vitro Syk kinase assay luminescence emission spectra.

FIG. 4B is a plot showing dose-response inhibition of Syk bypiceatannol.

FIG. 5 is a schematic representation of a bioinformatics strategy foridentifying tyrosine kinase peptide substrates.

FIG. 6A shows sequences of potential kinase substrates and scores forLyn and Src.

FIG. 6B is an ELISA readout for time course assays for Lyn kinase usingthree peptides.

FIG. 6C is an ELISA readout for timecourse assays Src kinase assaysusing seven peptides.

FIG. 7 is an ELISA readout for timecourse assays Src, Lyn, Abl, and Sykusing SFAStide.

FIG. 8A is a luminescence emission spectra from an in vitro Abl kinaseassay using ABStide.

FIG. 8B is a plot of in vitro Abl kinase assay luminescence emissionspectra area.

FIG. 8C is an ELISA readout for a timecourse assay of Abl kinase usingABStide.

DETAILED DESCRIPTION

The methods and compositions provide for direct and specific monitoringof intracellular tyrosine kinase activity in physiological contexts. ASyk-specific biosensor peptide was developed by combining a Syk-specificpeptide based on a Syk substrate sequence, identified using abioinformatics approach, with other modular units including abiotinylated lysine for affinity capture of the substrate and a cellpenetrating peptide for delivery of the biosensor into cells. This Sykkinase peptide biosensor (SAStide) did not cause toxicity at theconcentration used in these studies, and was able to detectdose-dependent and time-dependent activation and inhibition ofendogenous Syk using physiologically relevant stimuli in cultured celllines as well as primary splenic mouse B cells. These resultsdemonstrate the potential for this strategy to be used in a multiwellplate ELISA assay to analyze Syk activity in contexts that could includestudy of signaling processes in a basic research setting and monitoringtherapeutic response in translational applications.

The SAStide biosensor was demonstrated to work in a complex,biologically-relevant system using Syk-deficient DT40 chicken B cells.Syk plays a key role in B cell signaling, but is partly dependent uponactivation of Lyn through antigen binding to the BCR. Stimulation ofSyk-deficient cells by cross-linking the heavy chain of the BCR in thepresence and absence of H₂O₂ allowed for the specificity of thebiosensor to be assessed in the context of Lyn kinase activation. In theabsence of Syk, phosphorylation of the biosensor was not increased abovebackground levels and did not change over time following BCR engagementin the absence of Syk, even when overall tyrosine kinase signaling wasamplified as a result of H₂O₂ exposure. Syk also plays a major role inoxidative stress signaling, and its activation during oxidative stressis the result of both its own activity (via autophosphorylation) as wellas other protein tyrosine kinases. Other kinases also become activatedduring oxidative stress (as observed via antiphosphotyrosine blotting),yet there was no increase in phosphorylation of the biosensor in theabsence of Syk under these conditions. Reconstitution of the Sykdeficient cells with Syk-EGFP resulted in phosphorylation of thebiosensor peptide under B cell receptor-activating conditions and in thepresence of oxidative stress. This suggests that even in a complexcellular environment, the Syk biosensor is selectively phosphorylated bySyk and not by Lyn or other activated tyrosine kinases in these cells.Together these results demonstrate that the biosensor is specific forthe detection of Syk activity in B cells and B cell model systems.

The compositions and methods of the invention offer the ability tomonitor kinase activation and inhibition by compounds such aspiceatannol and dasatinib in an intact cell. Isolation of a kinase fromthe cellular environment can alter its function by removing regulatoryproteins, eliminating alternatively spliced variants, alteringpost-translational modifications and/or disrupting subcellularcompartmentalization. Additionally, isolation of the kinase precludesevaluation of the contribution of off-target effects of the drug, whichcould potentially affect efficacy (positively or negatively) viainhibition of upstream signaling in addition to the direct inhibition ofthe target.

Using the SAStide biosensor, inhibition of endogenous intracellular Sykactivity in a dose-dependent manner by the Src-family kinase inhibitors,dasatinib, and piceatannol was detected.

Aside from its potential utility in basic research on the function ofSyk kinase, the straightforward workflow and compatibility of thisbiosensor substrate with the multiwell ELISA-style readout might beuseful in a translational setting to determine Syk kinasepharmacodynamics in patient B cell populations.

In accordance with one embodiment, kinase specific substrate peptides,e.g., Syk-, Btk-, a Src family kinase-, Jak2-, or Abl-specific substratepeptides, were designed, synthesized, and screened for the ability to bephosphorylated by their respective specific kinases. These substratescan be used to identify and quantitate specific kinase activity eitherin vitro or in vivo. In accordance with one embodiment, the substratepeptide is introduced into cells and subsequently recovered to indicatethe kinase activity in a living cell. In accordance with one embodiment,the substrate peptide is introduced into the cell using any method,including any of several standard techniques known in the art,including, for example, microinjecting, electroporating, optoporating,vesicle fusing, pinocytic loading, or associating said substratemolecules with membrane permeant peptides. In accordance with oneembodiment the substrate peptide is linked to a cell penetratingpeptide. In one embodiment the substrate peptide is covalently linked toa cell penetrating peptide, optionally through a cleavable linker, toform a biosensor that will be taken up by living cells.

In some embodiments, the kinase substrate peptide can be linked to acell penetrating peptide to form a biosensor that can be used to measurespecific kinase activity in living cells. In one embodiment the cellpenetrating peptide (CPP) is a protein transduction domain or a fragmentthereof. Examples of useful CPPs include, but are not limited to, theTAT peptide (SEQ ID NO:35), and the protein transduction domains ofPenetratin (pAntp) (SEQ ID NO:48), Transportan (SEQ ID NO:50), MPG (SEQID NO:49), MPGdeltaNLS (SEQ ID NO:50), and pHLIP (SEQ ID NO:52). Cellpenetrating fragments of CPPs can also be used in a delivery systemand/or method of the invention. As used herein, the term CPP includescell penetrating fragments of protein transduction domains. Inaccordance with tone embodiment the cell penetrating peptide comprisesthe sequence of RKKRRQRRR (SEQ ID NO:35). In certain embodiments, theCPP can comprise or consist of D-amino acids and/or L-amino acids. Forexample, a CPP can consist entirely of D-amino acids or entirely ofL-amino acids; or a CPP can comprise a mixture of D- and -amino acids.

In certain embodiments, the amino acid sequence of a CPP can be in theforward direction (i.e. a native peptide) or in the reverse direction.As used herein, reference to a CPP includes both the native and reversesequences. In one embodiment, the reverse sequence can be aretro-inverso peptide (i.e. the amino acid sequence is the reverse ofthe native sequence, and consists of D-amino acids). For example, theterm “TAT peptide” as used herein includes a retro-inverso TAT peptidecomprising a reverse sequence of the protein transduction domain (PTD)of the HIV-1 TAT protein. Examples of other suitable CPPs include,without limitation, the PTD of Penetratin (pAntp), Transportan, MPG,MPGdeltaNLS, and pHLIP.

In certain embodiments, the biosensor includes the substrate sequencelinked to one or more tags to facilitate purification of the biosensorand/or to adhere the biosensor to a substrate. In one embodiment the tagis a peptide tag such as His6 (six consecutive histidine residues). Inan alternative embodiment the tag is an antigen or biotin. In certainembodiments, the biosensor includes a substrate sequence, a tag, and aCPP.

In certain embodiments, the methods can be used to predictresponsiveness of a cancer to a therapeutic treatment using relativelyfew cells. For example, Bcr-Abl plays a major role in the pathogenesisof chronic myelogenous leukemia (CML), and is the target of thebreakthrough drug imatinib. Although most patients respond well toimatinib, approximately 30% never achieve remission or developresistance within 1-5 years of starting imatinib treatment. Evidencefrom clinical studies suggests that achieving at least 50% inhibition ofa patient's Bcr-Abl kinase activity (relative to their level atdiagnosis) is associated with improved patient outcomes, includingreduced occurrence of resistance and longer maintenance of remission. Incertain embodiments, a Bcr-Abl kinase activity assay is described thatcan be used to predict or monitor response to imatinib using MRM on atriple quadrupole mass spectrometer. MRM enabled reproducible, selectivedetection of the peptide biosensor at fmol levels from aliquots of celllysate equivalent to ˜15,000 cells. This degree of sensitivityfacilitates the miniaturization of the entire assay procedure down tocell numbers approaching 15,000, making it practical for translationalapplications in patient cells in which the limited amount of availablepatient material often presents a major challenge.

EXAMPLES

Materials and Methods

Cell culture and biological reagents. The DG75 and DT40 B cell lineswere grown to a density of 0.4×10⁶ cells/mL in RPMI-1640 mediumcontaining 7.5% FBS, 1 mM sodium pyruvate, 100 IU/mL penicillin, 100μg/mL streptomycin and 50 μM 2-metcaptoethanol. Additionally, DT40 cellmedium contained 1% chicken serum. Anti-chicken IgM and anti-mouse IgMF(ab′)₂ fragments were purchased from Bethyl Laboratories. Anti-humanIgM was purchased from Rockland Immunochemicals. Hydrogen peroxide waspurchased from Mallinckrodt. Anti-Syk (N-19) was purchased from SantaCruz Biotechnology. Anti-tubulin and anti-phosphotyrosine (4G10) werepurchased from Millipore. Anti-phospho Syk (Y525/526) was purchased fromCell SignalingTechnology.

Peptide Synthesis and Purification. Peptides were synthesized using‘Fast’ Fmoc solid-phase peptide chemistry with a Prelude ParallelPeptide Synthesizer (Protein Technologies). The synthesized peptideswere purified using a C18 reverse-phase column on an Agilent 1200preparative HPLC system. Peptides were characterized usingliquid-chromatography mass spectrometry (LC/MS) on an Accela/LTQ system(Thermo-Finnegan) and matrix-assisted laser desorption/ionizationtime-of-flight mass spectrometry (MALDI-TOF/TOF) on a Voyager 4800instrument (Applied Biosystems).

In vitro kinase assay. Recombinant Abl, Src and Lyn enzymes wereobtained from a commercial source (Millipore). EGFP-conjugated Syk wasisolated from DT40 chicken B cells stably expressing Syk-EGFP.GFP-conjugated Lck was isolated from Jurkat cells stably expressingLck-EGFP. Cells were lysed using a solution containing 1% Nonidet P-40,50 mM Tris-HCl pH 8.0, 100 mM NaCl, 5 mM EDTA, 1 mM sodiumorthovanadate, 2 mM NaF and 1× mammalian protease inhibitor cocktail(Sigma). Syk- and Lck-EGFP were immunoprecipitated using GFP-Trap_Abeads (Chromotek) or anti-GFP magnetic nanoparticle beads (MBL, Japan).Lysates were incubated with the beads for 1 h at 4° C. The kinase-boundbeads were washed and then used in the in vitro kinase assay. Syk-EGFP,Lck-EGFP, or purified Abl or Src kinase (0.1 U) were incubated withkinase reaction buffer (500 μM ATP, 5 mM MnCl₂, HEPES, pH 7.2)containing the peptide substrate at 25 μM. Aliquots (22 μL) were takenat designated time points and quenched in 0.5 M EDTA, pH 8.5 (22 μL).The quenched sample (1 μL) was diluted into ELISA-based detection washbuffer and analyzed as described below. For substrate comparison assays,kinase reaction conditions were as described above except that substrateconcentrations were 4 μM, and concentration of enzyme used per reactionwas 6 nM. The volume of aliquots diluted in an equal volume of quenchbuffer was 4 μl (for 8 μl total quenched volume), and the entirequenched amount was diluted into ELISA wash buffer and analyzed asdescribed below.

ELISA-based fluorescence detection. Samples were incubated in a 96-wellNeutravidin™ coated plate (Thermo Scientific) in Tris-buffered saline(TBS) containing 0.1% BSA and 0.05% Tween 20 for 1 h at room temperatureon a short-radius plate shaker (600 rpm). Following incubation, wellswere washed three times with wash buffer (TBS, 0.1% BSA, 0.05% Tween20), then incubated with mouse anti-phosphotyrosine monoclonal antibody4G10 (1:5000 dilution in wash buffer, 100 μL per well) for 1 h at roomtemperature with shaking. Wells were washed three times with wash bufferand incubated with horseradish peroxidase-conjugated goat anti-mouseimmunoglobulin G (IgG) secondary antibody (Abcam) (1:1000 dilution inthe wash buffer, 100 μL per well) for 1 h at room temperature withshaking. Wells were then washed three times with wash buffer and twicewith sodium phosphate buffer (0.05 M, pH 7.5). For chemifluorescencedetection, Amplex Red™ reaction buffer (100 μL total volume/well)consisting of Amplex Red™ reagent (50 μL) (Invitrogen), 20 mM H₂O₂ (500μL) and sodium phosphate buffer (4500 μL) and allowed to react for 30min. Fluorescence of Amplex Red™ was measure using a Synergy4 multiwellplate reader (Biotek) with an excitation wavelength of 532 nm andemission wavelength of 590 nm.

Peptide biosensor assay. Cells were cultured as described above,harvested and resuspended at a density of 8×10⁶ cells/mL (8 mL), thentreated with the Syk biosensor peptide (25 μM) for 15 min prior tostimulation with either anti-IgM antibody (5 μg/mL), H₂O₂ (3.33 mM) orboth. Aliquots of the cell suspension (1 mL) were harvested, lysed inPhosphSafe Extraction Reagent (EMD Millipore) containing 167 mM EDTA andfreshly prepared protease inhibitor cocktail (Roche) and flash frozen.Half the cell lysate from each sample was used for ELISA-basedfluorescence detection and the other for immunoblotting. Fordose-response experiments, cells were stimulated with varyingconcentrations of anti-IgM (2.5-10 μg/mL) or hydrogen peroxide (1-7 mM),harvested at 5 min post-stimulation and processed as described above.For immunoblotting, membranes were blocked in 5% goat serum for 1 h. Allprimary antibodies were incubated at a dilution of 1:1,000 for 1 h atroom temperature and visualized using an HRP-conjugated secondaryantibody (Pierce) and ECL reagents (PerkinElmer).

Cell-Based peptide SAStide biosensor assay. Cells were cultured asdescribed above, harvested and resuspended at a density of 8×10⁶cells/mL (8 mL), then treated with the SAStide biosensor peptide (25 μM)for 15 min prior to stimulation with either anti-IgM antibody (5 g/mL),H₂O₂ (3.33 mM) or both. Concentrations of peptide lower than 25 μMresulted in low signal to noise in detection of phosphopeptide using theELISA-based read-out, and no toxicity was observed in the presence ofthe peptide at 25 μM (similar to what was observed in previouslypublished work on Abl kinase). Aliquots of the cell suspension (1 mL)were harvested, lysed in PhosphoSafe Extraction Reagent (EMD Millipore)containing 167 mM EDTA and freshly prepared protease inhibitor cocktail(Roche) and flash frozen. Half the cell lysate from each sample was usedfor ELISA-based fluorescence detection and the other for immunoblotting.For dose-response experiments, cells were stimulated with varyingconcentrations of anti-IgM (2.5-10 μg/mL) or hydrogen peroxide (1-7 mM),harvested at 5 min post-stimulation and processed as described above.For immunoblotting, membranes were blocked in 5% goat serum for 1 h. Allprimary antibodies were incubated at a dilution of 1:1,000 for 1 h atroom temperature and visualized using an HRP-conjugated secondaryantibody (Pierce) and ECL reagents (PerkinElmer). Uniformity of theamount of peptide taken up was tested in a representative experimentusing Syk-EGFP reconstituted Syk(−/−) DT40 cells, and while there was avery slight (but not statistically significant) trend towards higherpeptide amounts over time, no significant difference was seen acrossconditions (see supporting information, FIG. S3).

Cell-based inhibition assay. Cells (4×10⁶ cells/ml) were pre-treatedwith varying concentrations of piceatannol or dasatinib for 30 min andwith the Syk biosensor peptide (25 μM) for 15 min. Cells were thenstimulated with anti-IgM antibody (5 μg/mL) and H₂O₂ (1 mM) andharvested after 5 min as described above.

Isolation of primary mouse splenic B-cells and primary cell biosensorassay. B cells were enriched from mouse spleens via panning. Cells 6 ml,5×10⁶ cells/mL) were treated with vehicle (DMSO), piceatannol (50 μM) ordasatinib (100 nM) for 1 h and with the Syk biosensor peptide (25 μM)for 15 min prior to stimulation. The cells were stimulated with anti-IgMF(ab′)₂ (5 μg/mL). Cells were harvested at 0, 5, 10 and 15 min followingstimulation, lysed and analyzed as described above.

Time-Resolved Luminescence Detection of Syk Kinase Activity ThroughTerbium Sensitization

Luminescence Emission Measurements. Emission spectra (both steady-stateand time-resolved) were collected on a Biotek Synergy4 plate readerequipped with a monochromator at 23° C. in black 384-well plates(Greiner Fluortrac 200). For time-resolved measurements, spectra werecollected after excitation at either 266 nm or 280 nm (as denoted inspecific experiments) with a Xenon flash lamp followed by a delay of 50μsec. A luminescence scan between 450-650 nm was collected in 1 nmincrements with 1 msec collection time and 10 readings per data point.Sensitivity (an instrument parameter similar to gain) was adjusted asnecessary and is reported where relevant.

Job's Plot. The molar fraction of the pSAStide biosensor and Tb³⁺ werecontinuously varied inversely of each other while maintaining a totalmolar concentration of 16 μM (i.e. 1 μM pSAStide and 15 μM Tb³⁺, 2 μMpSAStide with 14 μM Tb³⁺, . . . , 15 μM pSAStide and 1 μM Tb³⁺) for eachdata point. Luminescent emission spectra were collected as describedabove and the area under the emission spectra was used as the parameterfor quantification of complex formation as luminescent increases withcomplex formation.

Binding Affinity. Tb³⁺ binding to SAStide and pSAStide was measuredusing Tb³⁺ luminescence sensitized by the central tyrosine orphosphotyrosine residue of SAStide and pSAStide respectively. Tb³⁺ wasadded to 100 nM of either peptide at final concentrations ranging from 0to 20 μM. All experiments were carried out in 10 mM HEPES and 100 mMNaCl (pH 7.5) at a volume of 100 μL. After excitation of the samples at266 nm (pSAStide) or 280 nm (SAStide), Tb³⁺ luminescence emissionspectra between 450 to 650 nm were collected for 1 ms following a 50 μsdelay and 30 readings per data point. Background luminescence emissionwas subtracted from the peptide in the absence of terbium. The areaunder each spectrum was integrated and used as the metric forquantification. The data were fit to Eq. 1 by using KaleidaGraphnonlinear curve-fitting software, where I is the Tb³⁺ luminescence at agiven concentration, I_(max) corresponds to the maximum Tb³⁺ emission,[Tb³⁺]_(T) is the total Tb³⁺ concentration, [P]_(T) is the total peptideconcentration and K_(d) is the equilibrium dissociation constant.I=I _(m)*([Tb ³⁺]_(T) +K _(d) +[P] _(T))−√(([Tb ³⁺]_(T) +K _(d) +[P]_(T))²−4([Tb ³⁺]_(T) *[P] _(T)))/(2*[P] _(T))  (1)

In vitro kinase assay. EGFP-conjugated Syk was isolated from DT40chicken B cells stably expressing Syk-EGFP. Cells were lysed using asolution containing 1% Nonidet P-40, 50 mM Tris-HCl pH 8.0, 100 mM NaCl,5 mM EDTA, 1 mM sodium orthovanadate, 2 mM NaF and 1× mammalian proteaseinhibitor cocktail (Sigma). Syk-EGFP was immunoprecipitated usingGFP-Trap_A beads (Chromotek). Lysates were incubated with the beads for1 h at 4° C. The kinase-bound beads were washed and then used in the invitro kinase assay (0.4 μg/μL). Syk-EGFP was incubated with the kinasereaction buffer (3.4 μg Syk-EGFP, 100 μM ATP, 10 mM MgCl₂, 1 μM Na₃VO₄,leupeptin, aprotinin, 125 ng/μL BSA and 25 mM HEPES pH 7.5, total volume170 μL) containing SAStide at 37.5 μM at 30° C. Aliquots (20 μL) weretaken at designated time points (0.5, 5, 10, 15, 30, 45, 60 and 90 min)and quenched in 6 M urea (20 μL). The quenched samples were then treatedwith the luminescence buffer (500 μM Tb³⁺ and 500 mM NaCl, 10 μL) for atotal volume of 50 μL (final concentrations of sample components: 2.4 Murea, 40 μM ATP, 4 mM MgCl₂, 0.4 μM Na₃VO₄, leupeptin, aprotinin, 50ng/μL BSA and 10 mM HEPES pH 7.5). Luminescence emission spectra werecollected as described above and the area under each spectrum wasintegrated using GraphPad Prism. An additional aliquot (1 μL) of thekinase reaction mixture was taken at each time point for validation ofphosphorylation using an ELISA-based chemifluorescent assay. Briefly,each aliquot was quenched with 0.5 M EDTA and incubated in a 96-wellNeutravidin coated plate (15 pmol biotin binding capacity per well,Thermo Scientific) in Tris-buffer saline (TBS) containing 0.1% BSA and0.05% Tween 20 for 1 h. Following incubation, each well was washed withthe TBS buffer and the incubated with mouse anti-phosphotyrosinemonoclonal antibody 4G10 (Millipore, 1:10,000 dilution in TBS buffer)for 1 h. Following incubation, each well was washed with TBS buffer andincubated with horseradish peroxidase-conjugated goat anti-mouseimmunoglobulin G (IgG) secondary antibody (Abcam) (1:1000 dilution) for1 h. Wells were then washed and treated with Amplex Red reaction buffer(Amplex Red reagent, Invitrogen, 20 mM H₂O₂ and sodium phosphate buffer)for 30 min. Fluorescence was measured using a Synergy4 multiwell platereader (Biotek) with an excitation wavelength of 532 nm and emissionwavelength of 590 nm.

Dose-Response Inhibition Assay. Syk-EGFP (0.4 μg/reaction) was incubatedwith the kinase reaction buffer described above before adding SAStide inthe presence of DMSO (vehicle) or varying concentrations of piceatannolat 30° C. for 10 min prior to the start of the reaction. The reactionwas started with the addition of SAStide (37.5 μM, total reaction volume20 μL). Each reaction was quenched after 30 min in 6 M urea (20 μL). Thesamples were then treated with the luminescence buffer (500 μM Tb³⁺ and500 mM NaCl, 10 μL) for a total volume of 50 μL.

High-Throughput Screening Calculations. The Z′ factor was calculatedaccording to Eq. 2.z′=(μ_(pos)−3σ_(pos) /√n)−(μ_(neg)+3σ_(neg) /√n)/(μ_(pos)−μ_(neg))  (2)And the signal window was calculated according to Eq. 3SW=(μ_(pos)−3σ_(pos) /√n)−(μ_(neg)+3σ_(neg) /√n)/(σ_(pos) /√n)  (3)Where n is the number of replicates, μ_(pos) and μ_(neg) are the averageluminescence of the positive (pSAStide or uninhibited) and negative(SAStide or inhibitor treated EGFP-Syk) controls respectively; σ_(pos)and σ_(neg) are the standard deviation of the positive and negativecontrols.Strategy and Method to Facilitate Identification of Kinase SubstrateSequences Substrate Informatics

Predicting kinase substrate specificity is a binary classificationproblem as each sequence can be classified as phosphorylated (substrate)or non-phosphorylated (non-substrate). Establishing a method forpredicting of kinase substrate specificity requires having a wellcollected and curated data set of positive and negative sequences,identification of features to characterize the sequences as one of thetwo classes, and the development of a classifier trained from the knownsequences capable of making the prediction for new sequences.

In this study, for each kinase, an individual prediction model wastrained from a collection of non-redundant phosphorylated sequences.Output from positional probabilities and positional scanning peptidelibraries (PSPL) were taken as features to generate a positional scoringmatrix (PSM) for each kinase and the PSM score was used as theclassifier. The prediction model was then trained using the collectionof substrates and non-substrate sequence collected through n-fold crossvalidation.

Data Collection and Construction.

In this study, substrates for each kinase were gathered from theliterature as well as phosphorylation site repositories includingPhosphosite Plus, Phospho.ELM and the Human Protein Reference Database.Negative substrates derived from the proteins containing substratesequences and interacting proteins containing no substrate sequences.Additionally, a PSPL was used to determine empirical effects of eachamino acid on the catalytic efficiency of the kinase towards thesubstrate sequence.

Feature Extraction.

Positional Probability— Generally, there is a pattern in the regionssurrounding the phosphosite that a specific kinase phosphorylates. Toidentify features to characterize the two classes, substrate sequencealignment can be analyzed to identify redundant properties of variousamino acid side chains. The development of a matrix can display theobserved frequencies compared to the expected frequencies. These PSMmatrices can be used to generate a score for a given kinase and asubstrate. The higher the score the more likely the kinase is tophosphorylate the substrate. To characterize a sequence nine aminoacids, four amino acids on either side of the phosphorylation site wereconsidered in the score. These positions were chosen based on thedisorder in substrates. The probability matrix, PM, was calculated asfollows. It is experimentally known that kinase k phosphorylates nsubstrates (n₁, n₂, . . . , n_(n)) consisting of nine amino acids, fouron each side of the phosphorylation site. The frequency of each aminoacid at each position in the collection of substrates was computed,f_(j,i), where j is amino acid (A, C, . . . , W, Y) at position i (−4,−3, . . . , 1). Due to the limitation of identified substrates for somekinases, when j=0 for those amino acids the value of j=1/n, where n isthe number of substrate sequences for kinase k. The matrix values werecomputed by comparing the observed frequency, f_(i,j), within thesubstrates to the expected frequency (background frequency), b_(i,j),derived from the frequency of each amino acid in each protein containinga substrate sequence as well as non-phosphorylated interacting proteins.This allowed for the background of amino acids to reflect what kinasenaturally interacts. A probability matrix 20×9 was constructed for eachamino acid and position defined as s_(i,j)=f_(i,j)/b_(i,j).

Positional Scanning Peptide Library— The positional scanning peptidelibrary has been previously reported. For each array, peptidephosphorylation signals were quantified based on the median intensityfor each spot. The median intensity values were then backgroundcorrected and signal intensity were then normalized by the followingequation:Z _(ij) =m×(S _(ij) /ΣS _(ci))where Z_(ij) stands for the normalized score of amino acid j at positioni having a signal score S_(ij) and m stand for the total number of aminoacids. S_(ci) is the signal score of amino acid j at position i where iis defined in the summation of all the m amino acids.

Positional Scoring Matrix—The two individual matrices, PM and PSPLM,were multiplied to form the positional scoring matrix, PSM. The valuefor each amino acid can then be used to identify favorable andunfavorable residues at each position. Values greater than 0.9 wereconsidered favorable or permissive for the kinase, while values lessthan 0.9 were consider unfavorable or impermissive.

For an nonapeptide of a given amino acid sequence the product of alls_(i,j) values yields the raw probability score, S_(R).S _(R)=Π⁸ _(i=1) s _(i,j)The raw score was normalized by probability of any nonapeptide being asubstrate for kinase k, P_(s). P_(s) was determined by the number kinasesubstrates collected n plus the number of significantly peptides fromthe PSPL compared to the total number tyrosine center nonpeptides seenin substrate and interacting proteins and the 200 peptides from the PSPLfor kinase k.P _(s)=(n+x)/(n _(T)+200)S=S _(R)/(S _(R)+1/P _(S))Positional selectivity, S_(i), was determined by the ratio of the numberof significantly abundant residues found at the subsite, n^(sig) _(i,j),compared to the expected abundance from a random distribution, n^(sigaa)_(i,j), multiplied by the ratio of the number significantly abundant atthe subsite to the total number of residues, n^(aa) _(i,j).S _(i)([Σ_(j) n ^(sig) _(i,j)/Σ_(j) n ^(sigaa) _(i,j)]×[Σ_(j) n ^(sig)_(i,j)/Σ_(j) n ^(aa) _(i,j)])An amino acid was defined as being significantly abundant if itsfrequency was found to be greater than two standard deviations above themean. This selectivity can be used to identify the selectivity of givensites within the substrate for a given kinase. If a site isnonselective, the properties of the site can be tuned to allow forspecificity against other kinases or to allow for terbium binding. Moreselective sites should only consider the best residues for the design ofthe substrate.

Performance Evaluation. To evaluate the prediction performance of thealgorithm, receiver operating characteristic (ROC) curves werecalculated and plotted based on the specificities (Sp) and sensitivities(Sn) by taking different thresholds.Specificity(Sp)=TN/TN+FPSensitivity(Sn)=TP/TP+FNwhere, TP is the number of true positive predictions (phosphorylationpredictions in the positive data set), TN is the number of true negativepredictions (non-phosphorylated predictions in the negative data set),FN is the number of false negative (non-phosphorylated predictions inthe positive data set), and FP is the number of false positives(phosphorylation predictions in the negative data set). Areas under ROCcurves (AROC) were also calculated based on the integration and used asthe Mann-Whitney U statistic.

Additional characterization was performed by the following:Accuracy(Ac)=(TP+TN)/(TP+FN+TN+FP)Precision(Pr)=TP/(TP+FP)Equal Error Rate(EER)=(1−Sn)*(TP+FN)+((1−Sp)*(1−(TP+FN)))*0.01Matthews CorrelationCoefficient(MCC)=((TP×TN)−(FP×FN))/√(TP+FP)(TP+FN)(TN+FP)(TN+FN)

Generation of Kinase Focused Peptide Libraries. Kinase focused peptidelibraries were generated based on the values of the PSM. All s_(i,j)>0.9were chosen as potential residues at each position. Combinatorialpeptide sequences were generated from these residues and scored againsteach kinase. Those peptides that scored positive for the kinase ofinterest and negative for all other kinases were then selected forfurther screening.

Terbium Binding Screening. Following the generation of the focusedkinase library sequences were screened for the ability to bind terbiumin a phosphorylation-dependent manner. A BLOSUM 62 matrix was used togenerate a sequence similarity score between the focus library ofpotential kinase substrates and known terbium sensitizing substrate suchas α-syn Y125 (DPDNEAYEMPSEEG) (SEQ ID NO:33) and SAStide(GGDEEDYEEPDEPGG) (SEQ ID NO:12)

Terbium based in vitro kinase assays. Recombinant kinases were incubatedwith the kinase reaction buffer (15 nM kinase, 100 μM ATP, 10 mM MgCl₂,125 ng/μL BSA and 25 mM HEPES pH 7.5, total volume 180 μL) containing12.5 μM biosensor at 30° C. Aliquots (20 μL) were taken at designatedtime points (0.5, 5, 10, 15, 30, 45 and 60 min) and quenched in 6 M urea(20 μL). The quenched samples were then treated with the luminescencebuffer (500 μM Tb³⁺ and 500 mM NaCl, 10 μL) for a total volume of 50 μL(final concentrations of sample components: 2.4 M urea, 40 μM ATP, 4 mMMgCl₂, 50 ng/μL BSA and 10 mM HEPES pH 7.5). Luminescence emissionspectra were collected as described above and the area under eachspectrum was integrated using GraphPad Prism. An additional aliquot (2μL) of the kinase reaction mixture was taken at each time point forvalidation of phosphorylation using an ELISA-based chemifluorescentassay as previously described. Briefly, each aliquot was quenched with0.5 M EDTA and incubated in a 96-well Neutravidin coated plate (15 pmolbiotin binding capacity per well, Thermo Scientific) in Tris-buffersaline (TBS) containing 0.1% BSA and 0.05% Tween 20 for 1 h. Followingincubation, each well was washed with the TBS buffer and the incubatedwith mouse anti-phosphotyrosine monoclonal antibody 4G10 (Millipore,1:10,000 dilution in TBS buffer) for 1 h. Following incubation, eachwell was washed with TBS buffer and incubated with horseradishperoxidase-conjugated goat anti-mouse immunoglobulin G (IgG) secondaryantibody (Abcam) (1:1000 dilution) for 1 h. Wells were then washed andtreated with Amplex Red reaction buffer (Amplex Red reagent, Invitrogen,20 mM H₂O₂ and sodium phosphate buffer) for 30 min. Fluorescence wasmeasured using a Synergy4 multiwell plate reader (Biotek) with anexcitation wavelength of 532 nm and emission wavelength of 590 nm.

Dose-response Inhibition Assay. Kinase (15 nM) was incubated with thekinase reaction buffer described above before adding SAStide in thepresence of DMSO (vehicle) or varying concentrations of kinaseinhibitors (nilotinib, bosutinib, ruxolitinib) at 30° C. for 10 minprior to the start of the reaction. The reaction was started with theaddition of biosensor (12.5 μM, total reaction volume 20 μL). Eachreaction was quenched after 30 min in 6 M urea (20 μL). The samples werethen treated with the luminescence buffer (500 μM Tb³⁺ and 500 mM NaCl,10 μL) for a total volume of 50 μL.

High-Throughput Screening Calculations. The Z′ factor was calculatedaccording to Eq. 2.Z′=(μ_(pos)−3σ_(pos) /√n)−(μ_(neg)+3σ_(neg) /√n)/(μ_(pos)−μ_(neg))  [2]And the signal window was calculated according to Eq. 3SW=(μ_(pos)−3σ_(pos) /√n)−(μ_(neg)+3σ_(neg) /√n)/(σ_(pos) /√n)  [3]

Where n is the number of replicates, μ_(pos) and μ_(neg) are the averageluminescence of the positive (phosphorylated peptide or uninhibited) andnegative (unphosphorylated peptide or inhibitor treated) controlsrespectively; σ_(pos) and σ_(neg) are the standard deviation of thepositive and negative controls.

Detection of Bcl-Abl Kinase Activity

Cell-based Biosensor Assay for Multiple Reaction Monitoring to DetectBcr-Abl.

Three independent replicate experiments were performed for the timecourse with Western blot detection. Three side-by-side replicateexperiments with just one time point (5 min) were performed for the MRManalysis. K562 cells were cultured to log phase growth and seeded to5×10⁶ cells/ml in a six-well plate (3 mL per well). When necessary,cells were pre-incubated with imatinib (10 μM) for 1 h at 37° C.followed by incubation with three treatments: 25 μM peptide (dissolvedin PBS), 25 μM peptide+10 μM imatinib, and 25 μM peptide+1 μMpervanadate (prepared by reacting a solution of sodium orthovanadatewith H₂O₂, followed by heating at 95° C. to degrade excess H₂O₂). At theindicated time points (5, 30, 60 min), aliquots (1 mL) were collectedand centrifuged (2200 rcf, 1 min, 4° C.) to remove excess media. Tocollect any remaining cells in the wells from the final aliquot, allwells were washed with phosphate buffered saline (PBS, 400 μl) and thesewashes were combined with the collected cells. Cells were suspended inPBS (1 ml) to wash away excess peptide, centrifuged again (2200 rcf, 1min, 4° C.), and lysed using Phosphosafe Extraction Reagent (Novagen)supplemented with EDTA and protease inhibitor cocktail (Roche). Cellswere immediately flash-frozen in liquid nitrogen, thawed on ice for 15min, vortex mixed, and centrifuged to clarify (16,000 rcf, 15 min, 4°C.). The supernatant was collected, measured for total proteinconcentration using the BCA assay (ThermoFisher Pierce, Rockford, Ill.),flash frozen again and stored at −80° C. until use.

Enrichment and MALDI-TOF/TOF Analysis.

Biosensor peptide from samples generated as described above (in thecell-based biosensor assay section) was captured usingstreptavidin-coated MagneSpheres (Promega Corporation, Madison, Wis.).The beads (20 μl) were prepared by washing with 0.1%Octyl-j-glucoside/PBS (3×150 μl). K562 cell lysates (200 μg totalprotein) were incubated with the beads on a shaker (600 rpm, 60 min).Beads were captured using a MagnaBot 96-well magnetic capture device(Promega) and washed with 0.1% Octyl-(3-glucoside/PBS (3×150 μl) anddeionized water (3×150 μl). Peptide was eluted using 15 μL sample buffer(ACN/H2O/TFA, 50%/50%/0.1%). 0.5 μL from each sample was co-spotted withα-cyano-4-hydroxycinnamic acid (10% w/v) containing ammonium dihydrogenphosphate (5 mg/ml), dried and analyzed on a 4800 MALDI-TOF/TOF Analyzer(ABSciex). Selected ions were analyzed by MS/MS (specifying the parention mass for selection and CID) and sequenced de novo.

Western blot analysis. Samples of equal protein content (100 μg/lane)were diluted into Laemmli buffer and subjected to SDS-PAGE. Proteinswere transferred to nitrocellulose membrane and analyzed by Westernblotting. Membranes were split at the 15 kD mark and blocked in 3% milkin TBS-T overnight at 4° C., followed by blotting with the indicatedantibodies in 3% milk/TBS-T. The bottom membrane was blotted with:DyLight-649 labeled Streptavidin (1:1000, ThermoFisher Pierce) to detecttotal biosensor; 4G10 α-phosphotyrosine antibody to detect thephosphorylated biosensor. Upper section of the membrane was blottedwith: α-phospho-Abl (Y245) (1:1000, Cell Signaling), α-phospho-STAT5(Y694) (1:5000, Abcam) and α-phospho-CrkL (Y207) (1:1000, Abcam) todetect phosphorylation of endogenous sites in the Bcr-Abl signalingpathway. α-β-tubulin (1:100,000, Millipore) was used as a loadingcontrol. Blots were incubated with IR-dye-labeled secondary antibodies(Rockland Immunochemical) in 3% milk/TBS-T (1:10,000). Signals ofimmunoblots were visualized using the Odyssey system (LiCOR Biosciences,Lincoln, Nebr.), quantified using densitometry with Quantity One(Bio-Rad), and analyzed with GraphPad Prism software.

Sample Preparation and Digestion

Aliquots (18 μg each) of cell lysate samples were processed to separateproteins from lipids. Chloroform/methanol/water (2:2:1.8 v/v/v) wasadded to the samples and the mixture vortex mixed, followed bycentrifugation (5 min at 3000 rpm) to separate the chloroform andaqueous layers. The aqueous layer was retained and extracted again inthe same manner, after which the chloroform layers containing lipidswere discarded. The extracted protein in the aqueous layer was thenprecipitated with cold acetone prior to the digestion protocol, in whichthe samples were taken up in ammonium bicarbonate buffer (50 mM)containing 0.1% (w/v) RapiGest SF (Waters Corporation, Milford, Mass.)to give protein concentrations of 1 μg/l. Dithiothreitol (DTT, 10 mM)was added (1:1 per volume, for a final concentration of 5 mM) and thesample incubated at 60° C. for 30 min to denature the proteins. Aftercooling to room temperature, samples were incubated in the dark withiodoacetamide (final concentration 15 mM from 55 mM stock) for 30 min.Trypsin was added (0.5 μg) and the samples incubated at 37° C. for 18 h.Following digestion, samples were treated with TFA (10% stock to givefinal concentration 0.2% w/v) at 37° C. for 30 min. Samples were dilutedwith 0.01% TFA to 0.5 μg/dl, centrifuged to clarify, and the supernatantinjected directly onto the triple quadrupole LC/MS system (describedbelow) for analysis (2 μl per sample, for a total protein loading of ˜1μg). For calibration standards, Abl biosensor peptide and syntheticreporter segment were added into lysate at appropriate concentrations toresult in 5-250 fmol per 2 p injection, then digested and prepared asdescribed above.

LC-MS/MS Analysis

Tryptic peptides were separated on a nano-LC/MS system which includedAgilent 1100 Series capillary and nano flow pumps, micro-well platesampler with thermostat, and Chip Cube MS interface on the Agilent 6410Triple Quadrupole mass spectrometer (Agilent Technologies, Santa Clara,Calif.). The peptides were loaded at 3 μl/min on an Agilent chipcontaining a 40 nl enrichment column packed with Zorbax 300SB-C18 5 μmmaterial. The enrichment column was switched into the nano flow pathafter 5 min, and peptides were separated with an analytical column (0.75μm×150 mm) packed with C18 reverse phase ZORBAX 300SB-C18 5 μm materialat a flow rate of 0.3 μl/min. The chip is coupled to the electrosprayionization (ESI) source of the triple quadrupole mass spectrometer. Thepeptides were eluted from the column using a linear gradient ofincreasing acetonitrile. For the first 5 min, the column wasequilibrated with 5% acetonitrile/95% water/0.1% formic acid (mobilephase A) followed by a linear gradient of 5%-15% B (100%acetonitrile/0.1% formic acid) in 10 min, 15-22% B in 30 min, and22-100% B in 35 min. The column was washed with 100% B and thenequilibrated with A before the next sample was injected. Blankinjections were run between samples to avoid carryover.

Product ion scans were run on the triple quadrupole instrument andanalyzed using Skyline software (MacCoss Labs, WA) to develop a methodto monitor transitions from each peptide of interest. Quadrupole 1 and 3were run at unit resolution with a minimum dwell time of 30 msec. Usingthis method, peptides of interest were analyzed by multiple reactionmonitoring mass spectrometry (MRM-MS). Standard peptides weresynthesized and diluted into stock solutions in deionized water (usingdry weight as measured by analytical microbalance) and concentrationcurves (in fmol) were used for quantitation of the peptides in the celllysate samples.

Results

For initial design of Syk substrates, expected frequencies werecalculated from the occurrence of each amino acid in the phosphorylationsite-containing proteins, in order to normalize to the representation ofeach amino acid in all substrate proteins. An amino acid or property wasconsidered “significantly abundant” at positions in atyrosine-surrounding sequence if its frequency was two standarddeviations greater than the mean frequency of that amino acid anywherein the set of substrate proteins. “Selectivity scores” were thenassigned to each site based on the abundance of significant amino acidsand the properties observed at each site. The selectivity score for eachof the positions surrounding the tyrosine (−4 to +4) was calculatedbased on how over-represented the significantly abundant amino acidswere at a site compared to their expected frequencies. The higher theselectivity score, the more “selective” the kinase was for that site (inother words, the more the kinase preferred a certain amino acid at thatsite), while scores closer to one indicate marginal preference for thatsite by the kinase.

Syk was observed to showed high selectivity at the −4 to +3 subsites ofSyk substrates, while the +4 position demonstrated no selectivity. Sykfavors acidic residues at all the upstream sites as well as the +1 and+2 positions. In addition, some preference for asparagine at the −2 and+2 positions and valine at the +1 position were also identified.Finally, the +3 position displayed a preference for the amino acidsvaline and proline. Using this information for preferences at a givenposition, a Syk peptide substrate, DEEDYEEPDEP (SEQ ID NO:2), designatedSAStide, was developed. SAStide was incorporated with other functionalmodules to form a Syk biosensor peptide. These modules may include a tagfor affinity capture of the substrate, a cell penetrating peptide fordelivery of the biosensor into cells, and a cleavable linker, such as aphotocleavable amino acid, for release of the substrate from the rest ofthe biosensor to permit mass spectrometry-based analysis. In oneembodiment, the Syk biosensor has the sequenceGGDEEDYEEPDEPGGKbiotinGG-βNpa-RKKRRQRRR (SEQ ID NO:34), with abiotinylated lysine (K_(biotin)) for affinity capture of the substrate,the cell penetrating peptide RKKRRQRRR (SEQ ID NO:35), and thephotocleavable amino acid beta(nitrophenyl)alanine or βNpa, also knownas 3-(2-nitrophenyl)-3-aminopropionic acid.

Phosphorylation of SAStide by Syk In Vitro

Phosphorylation of the biosensor by Syk was assessed using an in vitrokinase assay. In control experiments to generate a standard curve,phosphorylated SAStide was demonstrated to bind reproducibly to thewells, and exhibited a linear increase in signal up to an amount ofphosphopeptide per well of 0.5 pmol, beyond which saturation of theELISA signal occurred. This validated that the amount ofantiphosphotyrosine antibody-related signal was proportionally relatedto the degree of peptide phosphorylation. A substantial increase insignal over time was observed, demonstrating that SAStide wasphosphorylated by Syk in vitro. SAStide was also assayed using Src, Abland Lyn kinases, none of which produced any significant signal forphosphopeptide.

Detection of Dose Dependent Activation and Inhibition of Syk in IntactCells.

The ability of the biosensor to detect dose-dependent activation of Sykin the context of BCR activation by anti-IgM and H₂O₂-induced oxidativestress in intact, living Burkitt's lymphoma DG75 B-cells was examined.Syk activity was analyzed after 5 min and compared to unstimulated cellsas a control. No signal above the reagent background was observed incells not treated with the peptide. BCR activation by anti-IgM resultedin increased phosphorylation of the biosensor in a dose-dependentmanner. Induction of oxidative stress in the B cells by hydrogenperoxide treatment also resulted in dose-dependent increases inphosphorylation of the biosensor. These results show the ability of thepeptide biosensor to detect dose-dependent changes in the Syk activityat endogenous levels of expression in live cells.

The ability of the biosensor to monitor dose-dependent inhibition of Sykusing the Syk-specific natural product inhibitor piceatannol and theSrc-family kinase inhibitor, dasatinib, a potential therapeutic Sykinhibitor, was examined. The inhibitors were assayed in a dilutionseries from 1 mM-100 pM. Dasatinib was found to have a greater potencythan piceatannol in inhibiting Syk phosphorylation of the biosensor.However, high concentrations of piceatannol in the presence of BCRactivation and oxidative stress were toxic to DG75 cells whereasdasatinib was not. The apparent IC₅₀ values, the concentration at whichSAStide phosphorylation was decreased by 50% compared to the controluninhibited cells, were calculated using the Hill function to be10.8±9.3 nM and 1.2±1.5 μM for dasatinib and piceatannol, respectively.These results are consistent with a reduction in the level of Syktyrosine phosphorylation as detected by Western blot analysis.

Time-dependence of Syk Activity Following Activation.

To examine the time dependence of Syk activity following stimulationthrough BCR and/or oxidative stress, DG75 cells were treated as aboveand Syk biosensor phosphorylation was analyzed every few minutes for thefirst 15 min following stimulation. BCR stimulation gave a rapidincrease followed by steadily maintained phosphorylation of thebiosensor. As expected, the addition of hydrogen peroxide following BCRstimulation gave a very robust increase in phosphorylation over the timecourse due to the amplified and extended BCR signaling. Oxidative stressalone also resulted in increased phosphorylation of the biosensor,peaking at 5 min and subsequently showing a slight decrease. Theseresults demonstrate that the SAStide biosensor is able to monitortime-dependent increases in Syk activity in live cells followingstimulation.

Determination of the SAStide Biosensor Specificity in Intact Cells

Selective phosphorylation of the SAStide biosensor was evaluated in thecontext of the complex intracellular environment. The specificity of thebiosensor as a substrate for Syk and not other tyrosine kinases in livecells was explored using DT40 chicken B-cells in which the endogenousgene for Syk has been eliminated by homologous gene targeting. Nosignificant change in phosphorylation of the biosensor was detected overthe time course following stimulation when compared to unstimulatedcontrol cells. These results indicate that the specificity of thebiosensor was maintained in living cells in the context of IgMengagement and BCR-activated signaling.

Hydrogen peroxide was added to amplify BCR-stimulated phosphorylation.As seen with the anti-IgM stimulation alone, no significant change inthe phosphorylation of the biosensor was detected over unstimulatedcells. Western blot analysis of tyrosine-phosphorylated proteinsdemonstrated amplified phosphotyrosine signaling compared to anti-IgMtreatment alone, indicating activation of multiple tyrosine kinases andinhibition of tyrosine phosphatases. No significant change in thephosphorylation of the biosensor was detected in cells treated only withhydrogen peroxide. These results show that even in the presence ofamplified and extended BCR-related and other H₂O₂-related signaling, theSAStide biosensor was not appreciably phosphorylated by other highlyactivated tyrosine kinases in Syk-deficient cells. This experimentserves as a highly relevant specificity control in the intracellularcontext, given that tyrosine kinase activity was dearly upregulated, yetnone of these activated kinases phosphorylated the biosensor peptide.

The same set of experiments was conducted in Syk (−/−) DT40 cells thathad been reconstituted with Syk-EGFP. In the presence of BCR stimulationby IgM, phosphorylation of the biosensor peptide increased approximately2-fold over unstimulated Syk-EGFP-expressing cells and decreasedslightly over time. When treated with H₂O₂ with or without concurrentBCR stimulation, biosensor phosphorylation signal increased moredramatically to approximately 12-fold over control. Phosphorylation ofthe biosensor was consistent with that observed by Western blot analysisfor the Syk autophosphorylation site and the known Syk substrate BLNK.

Detection of Syk Activity and Inhibition in Primary Mouse SplenicB-cells.

The ability of the biosensor to monitor Syk activity and response toinhibitor treatment in primary cells expressing endogenous levels of Sykwas examined in isolated mouse primary splenic B cells treated with thebiosensor peptide in the presence of piceatannol or dasatinib. Primary Bcells were treated with 10 nM dasatinib, 1 μM piceatannol or vehicle(DMSO) for one h prior to stimulation. The SAStide biosensor peptide wasadded 15 min prior to stimulation. The cells were stimulated bytreatment with anti-IgM F(ab′)₂ (5 μg/mL) and harvested 0, 5, 10 and 15min following stimulation. Stimulation of Syk activity following BCRengagement resulted in a rapid increase in phosphorylation of theSAStide biosensor (within approximately two minutes—the time required tohandle and process an aliquot of cells collected immediately afterstimulation) followed by a maintenance of phosphorylation over time ascompared to control unstimulated cells, which showed only backgroundlevels of phosphorylation-related signal. In the presence of eachinhibitor, the level of phosphorylation of the biosensor was decreased,giving a signal that was close to background levels. These results showthat the biosensor peptide is capable of detecting activation andinhibition of endogenous Syk kinase expressed at normal levels inprimary cells that exhibit physiologically relevant B cell receptorsignaling, and suggest that elevation of Syk activity is very rapid inresponse to B cell receptor engagement in these primary cells.

Time-Resolved Luminescence Measurements Increase Signal to Noise.

Based on the similarity of the arrangement of carboxylate groups aboutthe central tyrosine residue in SAStide and the motif found inα-synuclein, the atypical phosphorylation dependent terbium sensitizingpeptide (FIG. 1A), the use of SAStide as a probe for the detection ofSyk activity through terbium-sensitized luminescence was investigated.

Phosphorylated (pSAStide) and unphosphorylated (SAStide) forms of thepeptide were synthesized and steady-state luminescence of each 1:1 Tb³⁺complex with excitation at 266 nm through a monochromator (for highlyresolved excitation energy control) was measured (FIG. 1B). The optimalexcitation energy was determined to be 266 nm for pSAStide and 275 nmfor SAStide and were used for characterizing each species in complexwith terbium. At 266 nm excitation energy, pSAStide exhibited strongTb³⁺ sensitization and SAStide displayed weaker luminescence. Therefore,266 nm was used for all further analyses. While signal from SAStide wassomewhat mitigated by using 266 nm excitation energy, there was stillweak but significant luminescence from SAStide so the signal to noise(comparing pSAStide and SAStide luminescence) was relatively low (2:1).It was therefore decided to test whether chelation of Tb³⁺ with thephosphorylated vs. unphosphorylated peptide could be more easilydistinguished using time-resolved luminescence detection. In atime-resolved luminescence measurement, the short-lived backgroundluminescence is allowed to decay before measuring the luminescence ofthe chelated Tb³⁺ (FIG. 2). Time-resolved luminescence was performed bycollecting spectra from 15 μM peptide in the presence of 100 μM Tb³⁺ in10 mM HEPES, 100 mM NaCl, pH 7.0, λ_(ex)=266 nm, 1000 ms collectiontime, 50 μsec delay time and sensitivity 180. Time-resolved measurementssignificantly improved the signal to noise to 32:1 (FIG. 1C),demonstrating that taking advantage of the increase in Tb³⁺ luminescencelifetime in the presence of phosphotyrosine vs. unphosphorylatedtyrosine improved the ability to detect phosphorylation of SAStide. Theimprovement in the signal to noise ratio was accomplished by allowingthe short-lived signal of the unphosphorylated peptide to decay prior tocollection.

Physical Characterization of SAStide-Lanthanide Binding andLuminescence.

Binding studies were performed to determine the stoichiometry andaffinity of pSAStide-terbium complexation. The binding stoichiometry ofthe highest affinity complex was established using the Jobs method ofcontinuous variations. The area under the emission spectrum was used asthe metric to quantify the pSAStide-Tb³⁺ binding ratios. pSAStide andterbium individually displayed no detectable luminescence; therefore,any changes in luminescence could then be attributed the formation ofthe pSAStide-Tb³ complex. The Jobs plot displayed an increase in totalarea as the mole fraction of terbium increased to 0.5 followed by alinear decrease with further increases in the mole fraction. These dataindicated that the preferred binding stoichiometry of pSAStide-Tb³⁺binding is 1:1.

Binding affinities were also determined using Tb³⁺ luminescence as ameasure of complexation. Terbium was titrated in the presence of 100 nMpSAStide or SAStide and luminescence emission spectra were collected andintegrated. The binding curves displayed a hyperbolic increase inluminescence with increasing terbium concentrations from 0-20 μM(representing a large excess of terbium), with saturation between at 20μM characteristic of one site binding. Additional increases inluminescence, ranging up to three fold, were observed with increasingterbium concentrations, which mass spectrometry analysis suggested werelikely due to complexes containing multiple terbium ions. However, forthe remainder of this work detection of pSAStide was carried out with6.67 equivalents of terbium relative to peptide, thus the 1:1 bindingmode characterized by the initial hyperbolic increase was the mostrelevant to detection under conditions used subsequently for assays. Thecalculated K_(d) for the 1:1 pSAStide-terbium complex represented by thehyperbolic curve was 1.51±0.087 M, which is comparable to the affinitiesreported for other terbium binding peptides. The unphosphorylatedSAStide-terbium complexation displayed significantly weaker binding; the1:1 complex exhibited a K_(d) of 7.64±0.32 μM (5-fold weaker than forthe phosphorylated peptide). These results demonstrate thatphosphorylation increased the affinity of SAStide for Tb³⁺. Also, sincethe greatest fold change in signal for pSAStide-terbium vs.SAStide-terbium was observed for the 1:1 complex, this represented thebest ratio to maintain in subsequent kinase assays.

Measurements of the terbium luminescence lifetime were performed tocharacterize the photophysical properties of pSAStide-terbium andSAStide-terbium complexation. The hydration number (i.e. the number ofwater ligands (q) in the terbium coordination sphere) can be determinedvia the luminescence lifetime of the complex in H₂O vs. D₂O, since theterbium excited state is quenched by the —OH vibrational overtones ofH₂O but not D₂O. Luminescence spectra for the pSAStide:Tb³⁺ andSAStide:Tb³⁺ complexes were collected in various ratios of H₂O/D₂O. Theluminescence lifetimes were fitted to a single exponential decay andwere determined to be 2.02 ms and 2.48 ms in H₂O and D₂O respectivelyfor pSAStide:Tb³⁺. These lifetimes lead to a q value of 0.12 for thephosphopeptide complex, indicating nearly an absence of H₂O in the innercoordination sphere of terbium at equilibrium. The unphosphorylatedSAStide:Tb³⁺ had a comparably shorter lifetime in H₂O at 1.88 ms and alonger lifetime D₂O of 2.92 ms resulting in a q value of 0.66. Thesedata suggest the SAStide:Tb³⁺ contain closer to one H₂O in thecoordination sphere at equilibrium, resulting in more quenching of theterbium excited state, which manifested as a shorter lifetime. Thesedifferences are likely related to the greater luminescence intensityobserved for the phosphorylated vs. unphosphorylated peptide, and alsoto the longer lifetime of the phosphopeptide that enabled gating of thesignal for better dynamic range for discriminating the phosphorylatedfrom unphosphorylated species using time-resolved signal collection.

The quantum yield for the pSAStide-terbium complex was determined usingdiffusion-enhanced energy transfer from the complex to fluoresceinisothiocyanate (FITC). Luminescence emission spectra were collected inthe presence of varying concentrations of FITC with increasing delaytimes. The time-resolved emission spectra and corresponding lifetimeplots display an increase in emission intensity and a simultaneousdecrease in the lifetime with increasing concentrations of FITC, and thequantum yield calculated from these data was 0.34.

Quantitative Detection of Syk Kinase Activity Using Tb³⁺ Sensitization.To demonstrate the use of SAStide:Tb³⁺ as a biosensor for quantitativedetection of Syk activity, a calibration curve was established usingmixed ratios of SAStide and pSAStide in the presence of the kinase assaycomponents and quenching buffer conditions (MgCl₂, BSA, ATP, NaVO₄,protease inhibitors, piceatannol, DMSO, urea) at concentrationssufficient to mimic an appropriate background matrix for a kinase assaymeasurement (FIG. 3A). Luminescence emission spectra were collected forthe various SAStide/pSAStide ratios and the area under the curves wereintegrated. Controls showed limited interference from the components ofthe kinase assay and quenching conditions. The calibration curvedemonstrated that the emission spectral area increased linearly and waswell correlated with increasing percent phosphorylation (FIG. 3B).However, there was an increase in the basal signal in the absence ofpSAStide (relative to mixtures of just peptide and simple buffers) thatwas likely due to complexation of terbium with ATP. The three phosphategroups of ATP can provide an appropriate coordination environment andadenosine provides the appropriate chromophore for excitation(λ_(ex)=259 nm), giving rise to some background even with time-resolvedmeasurements. Compared to detection of pSAStide vs. SAStide in HEPESbuffer alone, this increase in background signal reduced the signal tonoise ratio (S/N) by half (FIG. 1C compared to FIG. 3B). However,despite this decrease excellent S/N (15.3:1) was still achieved.

The limit of detection (LOD) for phosphorylation was 3.8±0.51%, definedas the percentage of pSAStide that gave a signal area corresponding to3× the standard deviation greater than the baseline for unphosphorylatedSAStide in the quenched kinase reaction buffer (the negative control).The limit of quantification (LOQ) for phosphorylation was 7.4±0.52%,defined as the percentage of pSAStide that gave a signal area 10× thestandard deviation greater than the signal in the negative control. TheZ′ factor and the signal window (SW) were also calculated to determineif this sensor would be appropriate for use in a high throughputscreening (HTS) assay. The Z′ factor should be between 0.5 and 1 for anassay to be considered appropriated for HTS, as assays with a Z′ factorin this range exhibit a large dynamic ranges and wide separation ofpositive and negative results. Assays with a SW greater than 2 are alsoconsidered appropriate for HTS assays. Both parameters were calculatedfrom the mean emission and standard deviation of the spectral area fromtriplicate measurements of the negative control SAStide in the in vitroassay buffer and the positive control pSAStide in the same conditions.The Z′ factor and SW were determined to be 0.82 and 14.63, respectively,indicating that time-resolved terbium luminescence detection of SAStidephosphorylation is an appropriate method for HTS assays.

Detection of Syk activity in vitro was accomplished using Syk-EGFPimmunoprecipitated from engineered DT40 chicken B-cells with the kinasereaction buffer and quenching conditions described above. Afterpre-incubation of the enzyme with the kinase reaction mixture, SAStidesubstrate was added and aliquots of the reaction were quenched atvarious time points in urea (to denature the enzyme). Tb³⁺ was added andtime-resolved luminescence was measured (FIG. 3C). The areas under theemission spectra were calculated, the percent phosphorylation wasinterpolated from the calibration curve and plotted against time (FIG.3D). These data show that enzymatic phosphorylation of SAStide can bedetected using time-resolved Tb³⁺ luminescence. As a control to verifyphosphorylation, an additional aliquot was used for detection ofphosphorylation using an ELISA-based chemifluorescent assay (SupportingInformation Figure S9).

The potential of this strategy for use in inhibitor screening was alsoevaluated. The effect of the Syk inhibitor piceatannol was assayed in adilution series from 10 nM to 10 mM. Luminescence emission spectra werecollected and integrated (FIG. 4A). The areas were normalized to theDMSO control and reported as percent activity. The observed IC₅₀ forpiceatannol was 178±1.4 μM (FIG. 4B), consistent with that found in theliterature. The Z′ factor and SW were determined in the context of thedose-response inhibition assay, calculated from the standard deviationand mean from the normalized percent activity from triplicatemeasurements of the negative control (10 mM piceatannol) and thepositive controls (10 nM-500 μM piceatannol). Over all the positivecontrols the Z′ factor was greater than 0.5 and the SW was greater than2, demonstrating that the application of pSAStide:Tb³⁺ is appropriate asa HTS tool in practice.

Time-resolved Tb³⁺ luminescence measurements were demonstrated tosubstantially increase signal to noise and thus dynamic range forquantitative analysis of peptide phosphorylation. Time-resolvedluminescence detection has been employed in FRET-based assays for kinaseactivity (e.g. the LanthaScreen® assay from Life Technologies), howeverthese assays rely on Tb³⁺ chelation by a macrocyclic carrier conjugatedto an anti-phosphosite antibody coupled with a fluorescently labeledsubstrate, and Tb³⁺ itself is not involved in binding to thephosphorylated product of the kinase reaction. Therefore theLanthaScreen® technique depends on antibody availability and is anindirect, “off-line” measure of substrate phosphorylation. Exploitingthe binding and sensitization of Tb³⁺ directly with a phosphorylatedsubstrate is essentially “label-free,” since neither antibodies norfluorophore labels are required. Time-resolved measurementssignificantly improved the signal to noise of detection compared tosteady-state measurements by minimizing background signal. The abilityto discriminate between the coordination environments for Tb³⁺ bindingto the unphosphorylated vs. phosphorylated peptides based onluminescence lifetime facilitated the improvement we observed indistinguishing between species. Accordingly, phosphorylation of the Syksubstrate peptide SAStide could be applied for rapid, quantitative andsensitive detection of Syk kinase activity and inhibition by smallmolecule inhibitors with little to no interference from the componentsof the kinase reaction.

Besides the specific application to Syk kinase described here, thisstrategy has broad significance for detecting phosphorylation usinglanthanide sensitization. Time-resolved detection should expand thepossibilities for other peptide- and protein-based lanthanidesensitization approaches to achieve better dynamic range andsensitivity. This allows for leveraging existing Tb³⁺-sensitizingsubstrates for other kinases, as well as open a new avenue fordevelopment of novel substrates to achieve high-throughput compatibilityfor other kinase targets important in therapeutic development, thatotherwise may not have provided sufficient signal to noise withsteady-state measurements.

Identification of Kinase Specific Peptide Substrates Using Informatics

For each kinase studied, a positional matrix was calculated as describedabove and a biosensor was designed to contain an optimized substrate orrecognition sequence. These sequences were identified and optimizedthrough a bioinformatic approach, represented schematically in FIG. 5.This method uses a positional probabilities matrix of amino acids aboutthe phosphorylation sites of known biological substrates as well asempirical effects of amino acids from positional scanning peptidelibraries to generate of positional scoring matrix (PMS). This matrixwas used to guide the generation of a focused library of possible kinasespecific peptide substrates. The focused library was then filtered basedPSM scores classifying the sequences as substrate or nonsubstrates aswell as specific or nonspecific substrates; all nonspecific ornonsubstrate sequences were removed from the library. The remainingsequences were filtered again based on sequence alignment with knownterbium sensitizing peptides resulted in a more compressed library ofpotential kinase specific peptide substrates that also could potentiallysensitize terbium luminescence (Table 1). The N and C-terminal portionsof the substrates were modified by the addition of acidic residues tofulfill the requirements for terbium binding.

TABLE 1 Kinase Sequence Abl Arg Btk Csk Fyn Hck Jak2 BtkELDAYLENE (SEQ ID 0.0612 0 95.6392 0.006 0.2253 0.0012 0.0008 NO: 14)ELAGYLENE (SEQ ID 0.0346 0.0638 93.7059 1.7044 0.062 0 0.0008 NO: 15)ELDVYEEQL (SEQ ID 1.2227 0.0761 49.6728 1.153 0.4552 0.2007 0 NO: 16)ELDVYVEQT (SEQ ID 0.4478 0.0031 77.3199 7.8338 0.0542 1.4037 0.0008NO: 17) Src DEDIYEELD (SEQ ID 20.6833 35.8182 19.6472 65.0808 97.12830.386 0 Family NO: 18) EGDVYDFVE (SEQ ID 35.6824 4.8361 26.3009 1.46529.9397 98.3974 0.3513 NO: 19) NINDVYEQPE (SEQ ID 85.2393 36.6505 0.391711.6312 31.2519 0.3714 0.0083 NO: 20) EEDVYDMPD (SEQ ID 9.2966 88.91740.5655 0.4834 94.2591 39.9093 15.2417 NO: 21) EADVYDMPD (SEQ ID 5.842582.204 0.0148 0.0395 80.3145 33.3778 23.201 NO: 22) DLDIYEELD (SEQ ID1.4851 0.7 39.4363 7.7841 87.8142 0 0 NO: 23) EAHVYDMMD (SEQ ID 0.78119.6421 0 0.0016 6.185 0.2233 2.8372 NO: 24) Jak2 DPDRYIRTE (SEQ ID8.2503 0.1254 0.0031 0 0.0033 0.428 90.603 NO: 25) EGDRYLKLE (SEQ ID0.49 0.0627 1.3431 0 2.3798 0.8529 98.9811 NO: 26) EDGRYVQLD (SEQ ID6.4805 92.1246 0.0039 0.2689 11.2798 0.0025 99.3638 NO: 27)PKPRYVQLD (SEQ ID 1.3358 42.9285 0.0335 0.039 6.3076 0 93.3284 NO: 28)Abl DEVAYQAPF (SEQ ID 92.7371 38.9107 0.0031 9.4929 27.2398 26.91690.0025 NO: 29) DFIRYHFWV (SEQ ID 5.0133 99.7691 0 0 0 0.0012 0 NO: 30)DHIFYIPV (SEQ ID 96.8949 0.9753 0.1122 0.0125 2.7383 0.0325 0.06 NO: 31)DHIFYHIPV (SEQ ID 92.9239 32.2272 0.0047 0 3.4669 0.046 0.0217 NO: 32)Syk DEEDYEEPD (SEQ ID 58.0722 81.7725 0.8413 51.0911 17.5158 0.01840.0008 NO: 1) Kinase Sequence Lck Lyn Pyk2 Src Syk Yes BtkELDAYLENE (SEQ ID 0.0057 0.061 0.1556 1.8777 3.5421 0 NO: 14)ELAGYLENE (SEQ ID 0.0872 0.0066 0.0006 0.2035 0.509 0 NO: 15)ELDVYEEQL (SEQ ID 0.4667 0.0825 22.3633 21.3577 3.841 4.2402 NO: 16)ELDVYVEQT (SEQ ID 0.9273 0.0244 54.4835 6.0868 2.8502 0.126 NO: 17) SrcDEDIYEELD (SEQ ID 99.273 99.982 86.9454 99.205 95.6083 99.8831 FamilyNO: 18) EGDVYDFVE (SEQ ID 74.5148 96.3223 99.2952 88.5987 1.3542 94.7683NO: 19) NINDVYEQPE (SEQ ID 88.3116 12.3235 8.0806 93.3962 2.0012 75.5539NO: 20) EEDVYDMPD (SEQ ID 97.8776 74.7765 99.9145 98.5624 92.619279.0648 NO: 21) EADVYDMPD (SEQ ID 82.6225 18.1129 93.562 95.027 66.06131.6134 NO: 22) DLDIYEELD (SEQ ID 90.435 87.8526 57.5102 90.4999 86.112833.0636 NO: 23) EAHVYDMMD (SEQ ID 3.6951 3.9692 15.6708 93.0073 9.76430.1196 NO: 24) Jak2 DPDRYIRTE (SEQ ID 0 0.09 0 0.4496 0.18281 0.0192NO: 25) EGDRYLKLE (SEQ ID 0.0255 0.9411 0.0096 0.5649 9.6434 0.1037NO: 26) EDGRYVQLD (SEQ ID 0.8727 0.1078 2.5882 16.505 0.497 0.3881NO: 27) PKPRYVQLD (SEQ ID 0.1415 0.0282 0.511 0.399 0.0032 0.008 NO: 28)Abl DEVAYQAPF (SEQ ID 0.0017 1.2011 5.5276 17.1958 21.3202 38.6511NO: 29) DFIRYHFWV (SEQ ID 0 0.0047 0 0.0172 0 0 NO: 30) DHIFYIPV (SEQ ID0 0.2108 0 0.0119 0.3369 0.0016 NO: 31) DHIFYHIPV (SEQ ID 0 0.0103 00.004 0.0026 0.0016 NO: 32) Syk DEEDYEEPD (SEQ ID 41.0265 99.018213.0189 96.9995 99.983 97.5226 NO: 1)

Detection of kinase activity using the novel sequences identified in themethod disclosed herein is accomplished by three physical changes in thebiosensors following phosphorylation. Phosphorylation of the biosensorresults in the shift of the excitation wavelength from 275 nm fortyrosine to 266 nm for phosphotyrosine, binding affinity increases frommicromolar to nanomolar, and the hydration number of thephosphopeptide-terbium complex is reduced due to the completion of thecoordination sphere. All of these physical changes result in theincreased luminescence intensity and lifetime of the phosphorylated formof the biosensor compared to the unphosphorylated biosensor.

Design and Validation of a Src Family Kinase Peptide Biosensor

The development of a Src family kinase peptide biosensor was performedby analysis of substrates for the individual members of the Src-familyincluding Src, Lyn, Hck, Fyn and Yes tyrosine kinases. Unlike the otherkinases the redundancy in substrate preference amongst these familymembers made it difficult to discern selectivity for each. The motifidentified for these kinases was[D/E]-[D/E]-[D/E]-[I/L/V]-Y-[G/A/V/D/E]-[D/E/I/S/T]-[F/I/L/V]-[X].

The use of two different sequences GGEEDEDIYEELDEPGGK_(biotin)GG (SEQ IDNO:45) and GGDNEGDVYDFVEDGGK_(biotin) (SEQ ID NO:46), designated Srcfamily artificial substrate peptide A and B (SFAStide-A and SFAStide-B)respectively, was further explored.

Scores Versus the Substrate Efficiency

Scoring using the combined PM/PSPL algorithm was performed on sixsequences that ranked in the top quartile of all possible permutationsof the Src family motif. These peptides were synthesized and tested inin vitro kinase assays (conditions as before) using ELISA-based readoutfor detection. For Src kinase, it was observed that the scoringrepresented the empirical results if a threshold for determining a“positive” was set between a score of 99 and 96. In other words, both ofthe peptides that scored >99 for Src were efficient substrates, whilethose scoring <99 were not. Lyn predictions were not quite as accurate(with a >99 scoring sequence not being phosphorylated). The differencemay be due to the number of input “positives” in the training dataset,which is larger for Src (at 167 known substrates) but relatively smallfor Lyn (at 48 known substrates). This underscores the importance ofempirical validation to developing an efficient substrate when largedatasets are not available. Even when large datasets are available,empirical testing can help to define the score cutoff that should beused as a threshold. Results of the evaluation of Src-family substratesare shown in FIG. 6. The sequences of potential substrates (DEDIYEELD(SEQ ID NO:18), DEDVYEELD (SEQ ID NO:38), DEDDYVDVD (SEQ ID NO:39),DEEDYGDVD (SEQ ID NO:40), DEDDYEDVD (SEQ ID NO:41), DEDDYEDID (SEQ IDNO:42), and DKDIYEELD (SEQ ID NO:43) and scores for Lyn vs. Src areshown in FIG. 6A.

FIG. 6B shows an ELISA readout for a time course from Lyn kinase assaysusing three of the peptides, and Src kinase assays for seven peptidesare shown in FIG. 6C.

Characterization of Src Kinase Family-based Specificity

To evaluate the specificity of SFAStide-A in vitro kinase assays wereperformed with a small panel of kinases including Abl, Src, Hck and Syk.Phosphorylation of the biosensor was detected using an ELISA-basedchemifluorescent assay. FIG. 7 shows that The Src-family tyrosinekinases Lyn and Src will phosphorylate SFAStide-A efficiently, whereasthe non-Src-family tyrosine kinases c-Abl and Syk will not.

To evaluate the terbium luminescence increase of the biosensors bothphosphorylated and unphosphorylated forms were synthesized andsteady-state luminescence of each 1:1 Tb³⁺ complex was measured withexcitation at 266 nm through a monochromator. Excitation at 266 nm isthe orthogonal wavelength for the phosphorylated forms and exhibitedstrong Tb³⁺ sensitization and the unphosphorylated forms displayedweaker luminescence. While unphosphorylated signal was somewhatmitigated by using 266 nm excitation energy, there was still weak butsignificant luminescence from unphosphorylated form of the biosensor sothe signal to noise (comparing the phosphorylated and unphosphorylatedbiosensor luminescence) was low (2:1) for both biosensors. However,time-resolved measurements significantly improved the signal to noise to11:1 and 14:1 for SFAStideA and SFAStideB respectively, demonstratingthat again, taking advantage of the increase in Tb³⁺ luminescencelifetime in the presence of phosphotyrosine vs. unphosphorylatedtyrosine improved the ability to detect phosphorylated forms. Theimprovement in the signal to noise ratio was accomplished by allowingthe short-lived signal of the unphosphorylated peptide to decay prior tocollection.

Binding affinities were determined using Tb³⁺ luminescence as a measureof complexation. Terbium was titrated in the presence of 1 μMpSFAStide(A/B) or SFAStide(A/B) and luminescence emission spectra werecollected and integrated. The binding curves displayed a hyperbolicincrease in luminescence with increasing terbium concentrations from0-50 μM (representing a ratio of 1:1 peptide/terbium), with saturationbetween 1-50 μM characteristic of one site binding. The calculated K_(d)for pSFAStideA:terbium complex represented by the hyperbolic curve was0.77 μM, which is comparable to the affinities reported for otherterbium binding peptides. The unphosphorylated SFAStideA:terbiumcomplexation displayed significantly weaker binding; exhibited a K_(d)of 3.93 μM (5-fold weaker than for the phosphorylated peptide). Theseresults demonstrate that phosphorylation increased the affinity ofSFAStideA for Tb³⁺. Likewise, pSFAStideB displayed a K_(d) of 1.79 μMand SFAStideB demonstrated a K_(d) of 2.50 μM (1.4-fold weaker than thephosphorylated form). Also, since the greatest fold change in signal forpSFAStideA-terbium vs. SFAStideA-terbium was observed, this substratewas selected for subsequent kinase assays.

To evaluate the potential of pSFAStideA for use as a biosensor forquantitative detection of Src-family kinase activity, a calibrationcurve was established using mixed ratios of SFAStideA and pSFAStideA inthe presence of the kinase assay components and quenching bufferconditions (MgCl₂, BSA, ATP, DMSO, urea) at concentrations sufficient tomimic an appropriate background matrix for a kinase assay measurement.Luminescence emission spectra were collected for the variousSFAStideA/pSFAStideA ratios and the area under the curves wereintegrated. The calibration curve demonstrated that the emissionspectral area increased linearly and was well correlated with increasingpercent phosphorylation.

The limit of detection (LOD) for phosphorylation was 7.9%, defined asthe percentage of pSFAStideA that gave a signal area corresponding to 3×the standard deviation greater than the baseline for unphosphorylatedSFAStideA in the quenched kinase reaction buffer (the negative control).The limit of quantification (LOQ) for phosphorylation was 21.8%, definedas the percentage of pSFAStideA that gave a signal area 10× the standarddeviation greater than the signal in the negative control. The Z′ factorand the signal window (SW) were also calculated to determine if thissensor would be appropriate for use in a high throughput screening (HTS)assay. The Z′ factor should be between 0.5 and 1 for an assay to beconsidered appropriated for HTS, as assays with a Z′ factor in thisrange exhibit a large dynamic ranges and wide separation of positive andnegative results. Assays with a SW greater than 2 are also consideredappropriate for HTS assays. Both parameters were calculated from themean emission and standard deviation of the spectral area fromtriplicate measurements of the negative control SFAStideA in the invitro assay buffer and the positive control pSFAStideA in the sameconditions. The Z′ factor and SW were determined to be 0.79 and 13.7,respectively, indicating that time-resolved terbium luminescentdetection of SFAStideA phosphorylation is an appropriate method for HTSassays.

Activity of Hck (a Src-family kinase) in vitro was assayed usingrecombinant Hck with the kinase reaction buffer and quenching conditionsdescribed above. After pre-incubation of the enzyme with the kinasereaction mixture, the SFAStideA substrate was added and aliquots of thereaction were quenched at various time points in urea (to denature theenzyme). Tb³⁺ was added and time-resolved luminescence was measured. Theareas under the emission spectra were calculated, the percentphosphorylation was interpolated from the calibration curve and plottedagainst time. These data show that enzymatic phosphorylation ofSFAStideA can be detected using time-resolved Tb³⁺ luminescence.

Evaluation of SFAStideA for use in inhibitor screening.

The effect of the Src family kinase inhibitor nilotinib was assayed in adilution series from 10 pM to 100 μM. Luminescence emission spectra werecollected and integrated. The areas were normalized to the DMSO controland reported as percent activity. The observed IC₅₀ for nilotinib was195 nM, consistent with that found in the literature. The Z′ factor andSW were determined in the context of the dose-response inhibition assay,calculated from the standard deviation and mean from the normalizedpercent activity from triplicate measurements of the negative control(100 μM nilotinb) and the positive controls (10 pM-1 μM nilotinib). Overall the positive controls the Z′ factor was greater than 0.5 and the SWwas greater than 2 demonstrating that the application of pSFAStideA:Tb³⁺maintains its appropriateness as a HTS tool in practice.

Design and validation of an Abl peptide sensor

Bioinformatic analysis of substrate sequence preference revealed Abldisplayed a substrate motif of[E/D]-[E/D/H/P/V]-[I/V]-[I/F/V]-Y-[A/Q/D]-[P/T]-[F/P/V]-[D/P]. Thismotif is in agreement with previous reports of kinase substrate motifs;however, some novel features were extracted from the input data thatwere unique to the analysis including the identification of glutamine atthe +1 position as a preferable residue in the recognition sequence.Comparing the preferred residues at the +1 position with the otherkinases in the method only Csk displays the same preference at thisposition. To demonstrate the ability of this method to identify novelkinase specific substrates for Abl capable of sensitizing terbium thesequence GGDEDDNDEVAYQAPFEDGGK_(biotin)GG (SEQ ID NO:36), Abl artificialsubstrate peptide (ABStide), was synthesized.

ABStide specificity was evaluated using in vitro kinase assaydemonstrated that ABStide was specific for Abl against the Src-familykinase, Hck. These results were shown by terbium-sensitized luminescence(FIG. 8A and FIG. 8B) and confirmed by ELISA-based Amplex Redchemifluorescent assay (FIG. 8C).

Characterization of Bcl-Abl biosensor uptake and phosphorylation.

Uptake and phosphorylation of the Bcr-Abl biosensor peptide in apatient-derived CML model cell line K562 was evaluated using Westernblot. To confirm that intracellular Abl signaling was not disrupted,cell lysates were probed to examine the phosphorylation status of theBcr-Abl autophosphorylation site and the endogenous Abl substrates STAT5and CrkL. Cells were cultured to log phase growth then treated with theAbl biosensorEAIYAAPFAKKK_((γ-biotin))G-βNpa-GCGGAPTYSPPPPPGGRKKRRQRRRLL (SEQ IDNO:37) in the presence or absence of either imatinib or the phosphataseinhibitor pervanadate for 5, 30 or 60 minutes. The cells were thenharvested and lysed in detergent buffer containing EDTA, phosphataseinhibitors, and protease inhibitors before being flash frozen in liquidnitrogen. Lysates were processed as described above, separated bySDS-PAGE and analyzed by Western blot using a two-color LiCOR scannerfor quantitative detection of IR-dye labeled secondary antibodies andstreptavidin (to measure total peptide signal via the biotinylatedresidue). The peptide was readily taken up into K562 cells andphosphorylated. As expected, phosphorylation was inhibited in thepresence of imatinib and stabilized in the presence of pervanadate. Inthe presence of pervanadate, observed peptide levels decreased overtime. Because the lysis buffer contained a cocktail of proteaseinhibitors, it was unlikely that this degradation was occurringpost-lysis. Consistent with previous reports, the decrease in peptideover time was found to be due to degradation of the peptide once itenters the intracellular environment.

This was tested by exploiting the biotin affinity tag to capture peptidefrom lysate generated after 5 min incubation and analyzed it byMALDI-TOF/TOF mass spectrometry. Within just 5 min of exposure to cells(as well as approximately 2-3 min additional processing time for cellharvesting), essentially no intact peptide was observed, even forsamples treated with peptide alone (FIG. 3). Several fragments weredetected (along with photo-induced ion chemistry intermediates arisingfrom the UV laser ionization inherent in MALDI-TOF analysis, alsoobserved with the intact peptide as further discussed in the supportinginformation) and identified by MS/MS analysis to arise from C-terminaldegradation. In particular, the cell permeability tag, TAT, was almostcompletely removed from the C-terminus. However, the N-terminal“reporter” sequence (which contains the phosphorylation site forBcr-Abl) was still intact—that is, no corresponding N-terminallytruncated fragments were observed. Peptide in lysates was enriched usingstreptavidin-coated magnetic nanoparticles through the peptide'sbiotinylated reporter segment. From this workflow, phosphorylated andunphosphorylated peptides could be detected by MALDI-TOF in linearpositive and negative mode, however reproducibility and signal to noisewere poor (example spectra provided in the supporting information)—aproblem not previously encountered when working with engineered celllines. Accordingly, a more sensitive detection strategy was needed torobustly quantify the degree of biosensor peptide phosphorylation byBcr-Abl. In future work, it may be possible to improve sensitivity andreduce ambiguity by eliminating the photocleavable linker andstabilizing the peptide biosensor via the incorporation of residuesresistant to proteolysis.

Development of the MRM method for quantitative analysis. MRM wasevaluated to for improved sensitivity in the context of trypsin-digestedwhole cell lysate from cells incubated with the biosensor peptide. Oneadvantage of this approach is that because the tryptic fragment arisingfrom the “reporter” module of the biosensor is unnatural, it is notsubject to confounding background from the native proteins in the celllysate. Two transitions for each peptide were included in thedevelopment of the MRM method, to increase confidence in peptideidentity. A calibration curve was established for quantitation of theMRM signal from the tryptic fragments of the biosensor peptide and itssynthetically phosphorylated derivative, which were added 1:1 at variousconcentrations into trypsin-digested K562 lysate (1 μg/μl). Signals forboth the modified and unmodified form of the Abl biosensor peptide wererobust and linear between 5 and 250 fmol. Analytical coefficients ofvariation (CV) were between 1-26% (depending on the transition). Onetransition from each peptide was chosen for quantitative analysis basedon its signal to noise and CV across the calibration range. Based on theratios of these transitions, the ratio of signals for the phosphorylatedand unphosphorylated peptides was approximately 1:1, with a CV of 4.3%across the entire concentration range, giving confidence in theanalytical reproducibility for quantifying the percent phosphopeptide ina sample.

Analysis of Abl biosensor phosphorylation. To analyze biosensorphosphorylation, K562 cells were incubated with the biosensor for 5minutes either alone or in the presence of Bcr-Abl inhibitor (imatinib)or phosphatase inhibitor (pervanadate) as described above. 1 μg of eachcell lysate was analyzed using the MRM method described above. MRMsignal data were extracted as chromatograms and the substrate peptideand its phosphorylated derivative were identified by the presence ofboth transitions in their respective peaks at the retention timeexpected for these analytes from the calibration curve analyses. Somebackground peaks were observed in each extracted chromatogram, howevernone of these exhibited signal for both transitions and the expectedretention time. Because the intensities of the total ion chromatograms(TICs) for each analysis were not completely uniform, a characteristic,invariable peak in the TIC was integrated and used to calculate acorrection factor for each MRM chromatogram. After this correction wasapplied, the peaks specific to the unphosphorylated and phosphorylatedpeptides were integrated and interpolated to determine the amount ofunphosphorylated and phosphorylated peptides in each sample. Asexpected, both unphosphorylated and phosphorylated peptides weredetected in the samples treated with peptide alone. No phosphorylatedpeptide was detected in the samples pre-treated with imatinib, andhigher levels (relative to peptide alone) of phosphorylated peptide weredetected in the samples treated with phosphatase inhibitor. Differencesbetween % phosphorylation observed in the peptide only andpeptide+pervanadate samples were statistically significant (p<0.05,one-way ANOVA with Tukey post-test), as well as being significantlydifferent compared to the absence of phosphopeptide seen in thepeptide+imatinib samples (p=0.044 and 0.025, respectively, one samplet-test).

All peptides were detected at levels above both their LOD and LOQ. Thefmol-scale levels of peptide detected here may represent the entirety ofmaterial taken up into cells and isolated by lysis, or it may representthe remaining reporter segment present after some degree of degradation.MALDI-TOF analysis of degradation indicated that N-terminal degradationdid not appear to be taking place, however it is still possible that thefragments were just not observable. Nonetheless, MRM-based detection ofthe N-terminal tryptic fragment was for the most part reproducible: CVsfor analyte quantification were acceptable (20% for unphosphorylated and23% for phosphorylated species) for the samples treated with peptidealone. CVs for the imatinib and pervanadate treated samples weresomewhat higher (˜42% for total peptide detection, unphosphorylated plusphosphorylated, from each) and considerably higher (71%) for the amountof phosphopeptide detected in the pervanadate treated samples. Comparingthese results to the Western blot detection, the CVs for streptavidinband intensities were lower for the peptide only and imatinib treatedsamples (11% each) but comparable (32%) for the pervanadate treatedsample. CVs for the 4G10 signals of the peptide only (12%) andpervanadate (68%) samples were more similar to the CVs from MRM. Forimatinib treated samples, 4G10 Western blot CVs were much higher due tothe background intensity which was not a factor in the MRM analysis.While these two experiments and methods cannot necessarily be directlycompared (for example, the analytical variabilities may be differentbetween the two techniques, and the ratio of 4G10/streptavidin signal isuncalibrated and thus cannot give a % phosphopeptide), this at leastshows that the results from MRM analysis are correlated with thoseobserved using the traditional Western blot analysis. Based on theexcellent analytical CVs obtained from the MRM calibration curveexperiments, the higher CVs observed for the imatinib and pervanadatetreated samples most likely reflect biological or sample processing andhandling variability (e.g. peptide uptake, the enzymatic reaction takingplace, level of phosphatase inhibition, and small differences in e.g.lysis and/or handling) rather than analytical variability. Whenself-normalized to represent the % phosphopeptide compared to total, CVswere within an acceptable range (20-40%) for all samples, given thebiological variability involved in a cell-based enzyme activity assay.

Taken together, these results demonstrate that accurate and reproducibledetection of Bcr-Abl biosensor peptide phosphorylation and inhibition inan intracellular assay. Using K562 cells as a human CML model system,substantial improvements in the lower detection limits for the assayread-out are shown compared to previous detection strategies. The amountof total sample analyzed (1 μg) is equivalent to approximately 15,000cells, indicating that it is possible to achieve several orders ofmagnitude improvement in sensitivity compared to Western blot orMALDI-TOF detection. This level of sensitivity and technicalreproducibility for the detection method should enable miniaturizationof the assay procedure and application to clinical material.

It is claimed:
 1. A biosensor comprising: a peptide substrate thatincludes a sequence selected from the group consisting of ELDAYLENE (SEQID NO:14), ELAGYLENE (SEQ ID NO:15), ELDVYEEQL (SEQ ID NO:16), ELDVYVEQT(SEQ ID NO:17), DEDIYEELD (SEQ ID NO:18), EGDVYDFVE (SEQ ID NO:19),NNDVYEQPE (SEQ ID NO:20), EEDVYDMPD (SEQ ID NO:21), EADVYDMPD (SEQ IDNO:22), DLDIYEELD (SEQ ID NO:23), EAHVYDMMD (SEQ ID NO:24), DPDRYIRTE(SEQ ID NO:25), EGDRYLKLE (SEQ ID NO:26), EDGRYVQLD (SEQ ID NO:27),PKPRYVQLD (SEQ ID NO:28), DEDVYEELD (SEQ ID NO:38), DEDDYEDID (SEQ IDNO:42), DKDIYEELD (SEQ ID NO:43), DEDDYGDVD (SEQ ID NO:44),GGEEDEDIYEELDEPGGK_(biotin)GG (SEQ ID NO:45), andGGDNEGDVYDFVEDGGK_(biotin)GG (SEQ ID NO:46), the substrate specific fora tyrosine kinase selected from the group consisting of Btk, Src familykinases, and Jak2; and at least one of a cell penetrating peptide and anaffinity tag, the cell penetrating peptide and/or tag linked directly orindirectly to the peptide substrate.
 2. The biosensor of claim 1,wherein the peptide substrate includes a sequence selected from thegroup consisting of ELDAYLENE (SEQ ID NO:14), ELAGYLENE (SEQ ID NO:15),ELDVYEEQL (SEQ ID NO:16), and ELDVYVEQT (SEQ ID NO:17).
 3. The biosensorof claim 1, wherein the peptide substrate includes a sequence selectedfrom the group consisting of DEDIYEELD (SEQ ID NO:18), EGDVYDFVE (SEQ IDNO:19), NNDVYEQPE (SEQ ID NO:20), EEDVYDMPD (SEQ ID NO:21), EADVYDMPD(SEQ ID NO:22), DLDIYEELD (SEQ ID NO:23), and EAHVYDMMD (SEQ ID NO:24).4. The biosensor of claim 1, wherein the peptide substrate includes asequence selected from the group consisting of DPDRYIRTE (SEQ ID NO:25),EGDRYLKLE (SEQ ID NO:26), EDGRYVQLD (SEQ ID NO:27), and PKPRYVQLD (SEQID NO:28).
 5. The biosensor of claim 1, wherein the biosensor comprisesthe sequence GGEEDEDIYEELDEPGGK_(biotin)GG (SEQ ID NO:45).
 6. Thebiosensor of claim 1, wherein the biosensor comprises the sequenceGGDNEGDVYDFVEDGGK_(biotin)GG (SEQ ID NO:46).
 7. The biosensor of claim1, wherein the cell penetrating peptide includes a sequence selectedfrom the group consisting of GRKKRRQRRRPPQ (SEQ ID NO:47), RKKRRQRRR(SEQ ID NO:35), RQIKIWFQNRRMKWKK (SEQ ID NO:48),GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO:49), GALFLGFLGAAGSTMGAWSQPKKKRKV(SEQ ID NO:50), GALFLGFLGAAGSTMGA (SEQ ID NO:51), andEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT (SEQ ID NO:52).
 8. The biosensor ofclaim 1, wherein the affinity tag includes a moiety selected from thegroup consisting of biotin and His6 chemical groups.